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ABSTRACT
MODULATION OF TGFp-INDUCED PAI-1 EXPRESSION BY CHANGES IN 
ACTIN POLYMERIZATION IN HUMAN MESANGIAL CELLS
Keyur Pravinchandra Patel 
Old Dominion University, 2006 
Director: Dr. William F. Glass II
Chronic renal diseases show increased deposition of extracellular matrix 
(ECM) in the glomerulus (glomerulosclerosis). Glomerulosclerosis is associated 
with activation of normally quiescent glomerular mesangial cells into 
myofibroblast-like cells. The overall objective of this study is to delineate cellular 
mechanism/s of myofibroblast-differentiation in disease states. In cultured 
mesangial cells certain characteristics of myofibroblast differentiation (a-smooth 
muscle actin (a-SMA) and hypertrophy) are associated with an increase in 
polymeric actin microfilaments (stress fibers). It is likely that other genes are also 
regulated in an actin cytoskeleton-dependent manner during myofibroblast 
differentiation. In these studies, we therefore examined the hypothesis that 
changes in the actin cytoskeleton regulate myofibroblast differentiation of 
mesangial cells.
In vivo, myofibroblasts play a major role in ECM accumulation and tissue 
scarring. TGFp increases ECM deposition by increasing plasminogen activator 
inhibitor type-1 (PAI-1) expression. PAI-1 inhibits ECM degradation by tissue- 
(tPA) and urokinase-type (uPA) plasminogen activators. Additionally, the Rho 
family of GTPases is required for TGFp-induced PAI-1 expression. Since, 
regulation of actin cytoskeletal organizaton is a major function of Rho, the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
hypothesis that Rho-mediated changes in actin cytoskeleton modulate PAI-1 
expression in glomerular cells was proposed. The effects of modulating the actin 
cytoskeleton on TGFp-induced PAI-1 expression were examined in cultured 
human glomerular mesangial cells. Inhibitors of Rho signaling decreased basal 
and TGFP-induced PAI-1 mRNA and protein expression. These effects were 
mimicked by direct inhibition of actin polymerization by Cytochalasin B (CytB) 
suggesting that the effects of Rho on PAI-1 expression are mediated through the 
actin cytoskeleton. CytB also inhibited the activity of a PAI-1 promoter. 
Conversely, stabilization of actin microfilaments with jasplakinolide (JAS) had the 
opposite effect on TGFp-induced PAI-1 expression. These results indicate a bi­
directional regulation of PAI-1 by the actin cytoskeleton depending on the state of 
actin polymerization. In contrast to inhibition of PAI-1, actin-depolymerizing 
agents increased tPA mRNA expression.
In summary, the changes in the actin cytoskeleton mediate the effects of 
Rho-GTPases in modulation of PAI-1 and tPA expression in response to TGFp. 
Thereby, they may control ECM degradation. Overall, the results suggest that 
changes in organization of the actin cytoskeleton regulate myofibroblast 
differentiation and ECM accumulation by coordinately modulating expression of 
multiple genes.
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1CHAPTER 1 
INTRODUCTION
Over 25 million people in the USA suffer from different forms of chronic 
renal diseases, of which approximately 419,000 have end stage renal disease 
(ESRD) with an annual increase of 4.6% [1]. Dialysis and organ transplant are 
the two mainstays of treatment of ESRD, both of which provide a palliative 
treatment at best and are associated with many limitations [2], The current 
preventive measures are only effective if instituted early in the disease process, 
which is clinically difficult to achieve since early disease is generally 
asymptomatic [3]. An annual expenditure of $ 25 billion for treatment of ESRD 
and lack of definitive treatment warrant further medical research on mechanisms 
leading to end state renal diseases [1].
The information in this chapter is organized into two parts: The role of 
activated mesangial cells in pathogenesis of chronic renal diseases and the 
observations with cultured mesangial cells leading to the central hypothesis are 
described first (sections 1.1 and 1.2). The second part contains information on 
actin cytoskeleton and the protein of interest of this study (sections 1.3 to 1.7). 
Mesangial cells and glomerulosclerosis 
The glomerulus
The renal glomerulus, the primary site of filtration of waste products from
The model journal for this dissertation is Kidney International.
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2Fig. 1. Normal glomerulus. The renal glomerulus is a highly vascular structure 
formed by invagination of the afferent arteriole into a double-layered Bowman’s 
capsule and subsequent branching into capillaries (e) lined by endothelial cells 
(d). A parietal layer of simple squamous epithelium (a) and a visceral layer of 
podocytes (b) separated by Bowman’s space (c) form the Bowman’s capsule. 
The efferent arteriole drains the glomerulus. The point at which the two arterioles 
penetrate Bowman's capsule is called the vascular pole and the point at which 
ultrafiltrate leaves the glomerulus is called the urinary pole. The space in 
between the capillary loops is called the mesangium (meso= in between, 
angium= vessels) (f), which consists of the mesangial cells (g) and extracellular 
matrix laid by them.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3the bloodstream, is a highly vascular structure consisting of a network of capillary 
loops held together by mesangial matrix (Fig. 1) [4], At the vascular pole, the 
afferent arteriole invaginates into the double-layered Bowman’s capsule 
consisting of a parietal layer of simple squamous epithelium and a visceral layer 
of podocytes separated by the Bowman’s space (urinary space). The afferent 
arteriole branches into a tuft of capillaries with multiple loops, collectively called 
the glomerulus. The glomerulus is drained by the efferent arteriole, which leaves 
near the point of insertion of afferent arteriole. The space in between the capillary 
loops is called the mesangium (meso= in between, angium= vessels), which 
consists of the mesangial cells and extracellular matrix laid by them.
As the blood flows through the capillary loops, some of its constituents 
including the water, waste products and electrolytes are selectively filtered into 
the Bowman’s space (Fig. 1) [4], This ultrafiltrate is collected, at the urinary pole, 
by the proximal convoluted tubules to be further transferred to a downstream 
system of tubules and ducts. After a complex series of absorption, re-absorption 
and secretion, the ultrafiltrate is finally converted into the urine. 
Glomerulosclerosis
Glomerulosclerosis is a major feature of many renal diseases that 
progress to end stage renal disease (ESRD) [5, 6]. Pathologically, 
glomerulosclerosis is characterized by increased deposition of extracellular 
matrix (ECM) and gradual replacement of functioning renal tissue with non­
functioning fibrous tissue (Fig. 2). Different underlying mechanisms lead to a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
B. Chronic Glomerulosclerosis
ECM deposition and_ 
mesangial expansion
C. Global Sclerosis
Replacement of normal 
glomeruli by ECM —
Fig. 2. Glomerular morphology in normal and pathologic states. (A)
Glomerulus showing relatively low amounts of extracellular matrix in the 
mesangium (arrow), (B) chronic glomerulosclerosis showing increased amount of 
extracellular matrix deposition and resultant expansion of the mesangium 
(arrow), (C) end-stage renal disease showing complete replacement of the 
glomeruli by extracellular matrix (arrow) in a process called global sclerosis.
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5common pathological feature in the form of scarring of renal tissue [7], Increased 
formation of extracellular matrix leading to fibrosis begins in the mesangium, the 
intercapillary portion of the glomerulus composed of mesenchymal mesangial 
cells [8, 9]. Expansion of the ECM occurs as a result of deposition of type IV and 
type I collagen, and fibronectin. In chronic renal diseases, fibrosis results from 
increased matrix production, decreased matrix breakdown or both. Since filtration 
and removal of waste products from the blood are the major functions of 
glomerulus, patients with non-functioning glomeruli develop toxicity due to 
accumulation of waste products [10],
Renal fibrogenesis
Renal fibrogenesis typically occurs in three distinct phases, with the first 
two being similar to physiological wound healing, namely the phase of induction, 
the phase of inflammatory matrix synthesis and the phase of post-inflammatory 
matrix synthesis [7], The first phase is associated with an influx of mononuclear 
cells upon an insult leading to an inflammatory response. The inflammatory cells 
liberate cytokines and growth factors, which in turn activate fibroblasts [7], In 
particular, transforming growth factor p (TGFp), a pro-fibrotic growth factor, plays 
a major role in activating normally quiescent mesangial cells [11], The second 
phase of inflammatory matrix synthesis is characterized by increased synthesis 
of ECM and de novo expression of proteins, and reduced degradation of ECM. 
The structural changes are still potentially reversible throughout this phase [7], 
The third phase of post-inflammatory matrix synthesis is marked by autonomous
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6fibroblast proliferation, synthesis of ECM independent of the presence of primary 
inflammatory stimulus and perpetuation of the scarring process [7],
The mesangial myofibroblast
During the three phases described above, glomerular mesangial cells 
contribute to excess matrix deposition in multiple ways. Besides providing 
structural support to the mesangium, mesangial cells both secrete and respond 
to growth factors and inflammatory mediators, thereby regulating the glomerular 
microenvironment [12]. TGFp activates otherwise quiescent mesangial cells 
which now start proliferating and expressing proteins that contribute to ECM 
deposition (Fig. 3). These activated mesangial cells also express a-smooth 
muscle actin (a-SMA) de novo, which is normally seen in smooth muscle cells, 
[13-20]. Consequently, these activated mesangial cells with smooth muscle cell­
like properties are referred to as myofibroblasts. a-SMA expression and 
myofibroblast-like differentiation are also seen elsewhere in tissues such as 
heart, lung, liver and skin [21-24],
Along with a-SMA, activated myofibroblasts start expressing profibrotic 
plasminogen activator inhibitor-1 (PAI-1) de novo, which in turn inhibits ECM 
degradation and favors ECM deposition [19, 25], Thus, TGFp-mediated 
myofibroblast-like differentiation is associated with increased PAI-1 expression 
and excess ECM deposition that eventually leads to glomerulosclerosis and end- 
stage renal disease (Fig. 3).
The overall objective of this study is to characterize the mechanisms of 
mesangial myofibroblast-like differentiation in order to obtain useful insights into
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7(end result)
(disease phenotype)
(effector molecules)
(effector cells)
(initiating insult)
M esangial Cells
Glomerular Sclerosis
Chronic Renal D isease
Plasminogen Activator 
System
- More than 25 million patients
- Annual health care cost 25 billion
- Major feature of chronic and end stage renal diseases
- Excess deposition of extracellular matrix
- Glomerulus replaced by non-functional fibrous tissue
- Profibrotic growth factor, associated with renal fibrosis
- Increases matrix production directly
- Decreases matrix degradation by increasing PAI-1.
- Regulates the rate of matrix turnover
- Components:
- Activating: tPA and uPA; anti-fibrotic
- Inhibitory: PAI-1; profibrotic
- Mesangial = meso + angium = between blood vessels
- Structural support of glomerulus and capillary loops
- Site of production & action of growth factors & cytokines
- Express PAI-1 de novo in disease states
Fig. 3. Cascade o f events leading to chronic renal diseases. TGFp is a 
profibrotic growth factor that increases production of PAI-1 by glomerular 
mesangial cells. Increased production of PAI-1 leads to decreased degradation 
and increased deposition of extracellular matrix in mesangium resulting in 
glomerulosclerosis. Replacement of normal glomeruli by non-functional fibrous 
tissue in glomerulosclerosis leads to clinical presentation in the form of chronic 
and end-stage renal diseases, both currently irreversible disease processes.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8renal fibrogenesis. The specific aim of this study was to examine regulation of 
TGFp-induced PAI-1 expression in human mesangial cells.
Cultured mesangial cells as a model of myofibroblast phenotype
Cultured mesangial cells provide a useful in vitro model of myofibroblast 
phenotype. The phases of fibrogenesis can be mimicked in vitro by altering the 
culture conditions. Cell culture in the presence of serum provides cytokines and 
growth factors as seen in the phase I to activate mesangial cells (refer to section 
1.1.3). Cell culture in the absence of serum mimics phase III, which is marked by 
the absence of cytokines, development of the myofibroblast-like phenotype (a- 
SMA expression) and increased ECM production (refer to section 1,1,3). Thus, 
initial culturing in the presence of serum, followed by serum deprivation, mimics 
the growth factor and cytokine milieu of myofibroblast activation and 
differentiation. Primary cultures of human and rat mesangial cells were used in 
this study to understand mechanisms of myofibroblast differentiation.
Regulation of g-SMA expression in cultured mesangial cells
As a part of an overall focus on understanding the myofibroblast-like 
phenotype, our laboratory previously examined the regulation of a-SMA, 
expressed de novo upon myofibroblast differentiation, in cultured mesangial 
cells. Stephenson et al showed that serum-deprivation caused mesangial cells to 
spread, form abundant stress fibers, express more a-SMA and undergo 
hypertrophy [26]. Likewise, proliferating dermal fibroblasts are initially devoid of 
microfilaments [24], but their appearance and subsequent disappearance 
paralleled the expression of a-SMA. The observations of Stephenson et al and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9the in vivo data regarding dermal fibroblasts, suggested that clearance of growth 
factors increases actin polymerization thereby controlling myofibroblast 
differentiation. Since, expression of a-SMA paralleled changes in actin 
cytoskeleton organization, it was hypothesized that changes in actin 
polymerization regulate a-SMA expression and hypertrophy in mesangial cells. 
The Rho family of small GTPases regulate actin polymerization through the 
downstream effector, Rho-kinase (ROCK), in a variety of cell types [21]. Inhibition 
of actin polymerization by agents that inhibit Rho-kinase (Y-2632, HA-1077), as 
well as by the agents that directly bind to actin and affect its degree of 
polymerization (CytB, LatB), inhibited a-SMA expression and promoter activity 
[28]. On the other hand, stabilization of actin polymerization by JAS and 
phalloidin increased a-SMA expression and promoter activity. Similarly, 
mesangial cell hypertrophy was blocked by actin depolymerization. These results 
confirmed the hypothesis that changes in actin polymerization regulate a-SMA 
expression and hypertrophy in mesangial cells [28].
Central hypothesis
Like a-SMA expression and hypertrophy, de novo expression of PAI-1 is 
also seen with myofibroblast differentiation [29]. It is possible that a-SMA, PAI-1 
and multiple other genes are regulated by a common underlying mechanism that 
regulates overall myofibroblast differentiation. Therefore, a central hypothesis 
that changes in actin polymerization regulate myofibroblast-like phenotype by 
simultaneously regulating expression of multiple genes was proposed.
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10
The following sections contain information on the actin cytoskeleton, 
regulation of its organization, its role in gene expression, introduction to 
plasminogen activator system, regulation of PAI-1 expression and the specific 
hypothesis for this study.
Actin cytoskeleton and gene regulation
Traditionally, actin cytoskeletal organization is considered important for 
controlling processes such as cell shape and cell motility [30-32], At the same 
time there is increasing evidence suggesting that the actin cytoskeleton and cell 
shape are important regulators of gene expression and cell function. Early 
observations of Folkman and Moscona, showing an association between 
inhibition of cell spreading and decreased DNA synthesis, proposed that cell 
shape regulates cell function [33]. Over the past 20 years, studies by Ingber have 
supported the idea that mechanical transduction through cytoskeletal elements 
affect cell functions [34-38], Recent studies have shown that networks of actin 
polymers, also known as stress fibers, provide a highly specific and organized 
network of fibers for processes such as signal transduction and gene regulation. 
Localization of signaling molecules at specific cytoskeletal locations allows 
integration of signaling pathways and effective transmission of a signal [39, 40]. 
For example, MEKK1 that activates JNK mitogen associated protein kinase is 
associated with the actin cytoskeleton [41]. During keratinocyte differentiation, 
cytoskeletal association facilitates coupling of ErbB1 and ERK [42], Also, 
expression of genes such as a-SMA seems to be regulated by the state of actin 
polymerization [28]. Localization of mRNA and protein translation machinery at
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highly specific intracellular pockets of actin stress fibers have also been identified 
[43], Thus, current evidence points towards regulation of gene expression by 
actin cytoskeleton.
The actin cytoskeleton
The actin cytoskeleton, also known as the microfilament system, is an 
important structural component of all eukaryotic cells. Actin, a 42-kDa globular 
polypeptide, is the building block of the microfilamentous cytoskeletal system. 
Monomeric actin (G-actin) molecules polymerize via non-covalent interactions 
into filamentous actin also known as F-actin or stress fibers [44], Actin filaments 
cross-link with each other and with various cellular and membranous structures 
to form a highly organized network. The actin filaments traverse the cytoplasm 
and provide structural support to the cells. They transmit tension and resist 
deformation of the cells. Other cellular functions regulated by the actin 
cytoskeleton include but are not limited to cell shape, cell motility, cell division, 
cell-cell and cell-substrate interaction, transmembrane signaling, endocytosis, 
secretion and muscle contraction [45, 46],
The actin filaments are very dynamic structures undergoing constant 
growth in length at one end (barbed end, plus end) and attrition at the opposite 
end (pointed end, minus end). The rates of growth and attrition determine the 
amounts of monomeric and polymeric actin in the cell. Actin polymerization is 
regulated at multiple levels in response to extracellular stimuli or intracellular 
needs; and involves various cell-signaling pathways, actin binding and 
associated proteins (Fig. 4) [46],
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Fig. 4. Regulation of actin cytoskeleton organization by Rho GTPase. Rho
GTPase is a major regulator of actin polymerization. Rho-kinase (ROCK) and 
mDia are known downstream effectors of Rho that increase polymeric F-actin 
and decrease monomeric G-actin content by regulating the actions of actin 
binding proteins such as cofillin and profilin. The hypothesis examined in this 
thesis proposed that Rho-mediated changes in actin polymerization regulated 
expression of specific genes through involvement of some yet unknown factors. 
Agents that increase (Jasplakinolide) or block (Toxin B, HA-1077, Y-2632, 
Cytochalasin B and Latrunculin B) actin polymerization were used to test the 
hypothesis by modifying actin polymerization at different levels.
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Actin binding proteins
The actin cytoskeleton undergoes different stages of organization such as 
nucleation, polymerization, cross-linking, folding and movement. As the name 
implicates, actin-binding proteins bind to actin monomers or polymers during 
different phases of assembly and regulate the rate and the extent of actin 
polymerization. The activities of these proteins are in turn regulated by signaling 
molecules [46], Major actin-binding proteins are briefly reviewed in Table 1 [47- 
49],
RhoA and actin cytoskeleton
Rho is a member of Rho family of small GTPases (Rho, Rac and Cdc42) 
that plays a major role in organizing actin cytoskeleton in the form of stress fibers 
(Fig. 4) [27, 50, 51]. The Rho GTPases exist in an inactive GDP-bound form 
complexed with a GDP-dissociation inhibitor (Rho GDI) and an active GTP- 
bound form. In response to stimuli, guanine nucleotide exchange factors (GEFs) 
dissociate GDI from Rho and allow Rho to bind to GTP. Activated Rho-GTP in 
turn activates downstream effecters. GTPase activating proteins (GAP) inactivate 
Rho by catalyzing GTP hydrolysis [52], Rho-kinase or ROCK, is the main 
downstream effector of Rho that inactivates proteins that depolymerize actin 
such as cofilin and destrin and thereby facilitates actin polymerization. Other 
effectors of Rho include PIP-5 kinase and mDia, a 140 kDa protein that increases 
actin polymerization through the actin-binding protein profilin [53-55],
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Actin Binding Protein/s Effect on Actin Cytoskeleton
Profilin In resting state, sequesters monomeric actin
thereby inhibits actin polymerization, In
stimulated state, promotes assembly of actin
filaments
P-thymosin, twinfilin, DNAse I Binds to monomeric actin and sequesters it,
thereby inhibits actin polymerization
Cofilin Binds and severs actin filaments, Also
known as actin depolymerizing factor (ADF)
Gelsolin, villin, fragmin, adseverin, Bind and sever actin filaments
scinderin
Fascin, villin, fimbrin, a-actinin Cross-link actin filaments, Also known as
actin-bundling proteins
Srv2/cyclase-associated protein Stimulate nucleotide exchange on actin
(CAP) family proteins monomers and relieve the inhibitory effects
of ADF/cofilin on this exchange
Wiskott-Aldrich Syndrome Protein Increases nucleation of actin monomers
(WASP)
Arp 2/3 Binds to actin dimers and increases
nucleation of stress fibers
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Plasminogen activator system and plasminogen activator inibitor-1 in 
chronic renal disease
The plasminogen activator system, which controls activation of 
plaminogen into plasmin, is the key regulator of matrix degradation (Fig. 5). 
Activated plasmin, in turn, not only degrades some matrix proteins itself, but also 
amplifies the fibrolytic response by activating another set of powerful matrix 
degrading enzymes called matrix metalloproteinases (MMPs) [56]. PAI-1, tissue- 
type plasminogen activator (tPA) and urokinase-type plasminogen activator 
(uPA) are components of the plasminogen activator system (Fig. 5). PAI-1 
inhibits matrix breakdown by inhibiting tPA and uPA. Although tPA and uPA have 
a limited capacity to directly degrade ECM proteins, they trigger activation of a 
cascade of proteases that lead to ECM degradation (Fig. 5) [56]. The balance 
between the anti-fibrotic effects of plasminogen activators and the pro-fibrotic 
effects of PAI-1 determines the rate of matrix turnover and the amount of matrix 
deposition in the tissue [57, 58]. Transforming growth factor beta (TGFp) is a 
major profibrotic growth factor responsible for increased PAI-1 expression and 
resulting glomerulosclerosis seen in chronic renal diseases [59]. The 
plasminogen activator system also regulates fibrinolysis in the intravascular 
space [60]. 
tPA
Tissue-type plasminogen activator (tPA), Mr of 70,000, is secreted in the form of 
a single or double chain enzyme from endothelial and mesangial cells [61].
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Fig. 5. Regulation of extracellular matrix turnover by the plasminogen 
activator system. Plasminogen activator system consists of two activators of 
plasminogen namely tissue-type (tPA) and urokinase-type (uPA) plasminogen 
activators and their inhibitor called plasminogen activator inhibitor type I (PAI-1). 
Both tPA and uPA convert inactive plasminogen into active plasmin. Active 
plasmin, in turn, stimulates extracellular matrix (ECM) degradation mainly by 
activating matrix metalloproteinases (MMPs) and to a lesser degree by directly 
degrading ECM. PAI-1 acts as a gatekeeper of matrix degradation cascade by 
inhibiting tPA and uPA mediated plasminogen activation.
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The modular structure of tPA include five domains homologous to those of 
fibronectin, epidermal growth factor (EGF), plasminogen and trypsin-like 
protease. The extensive homology of domains of tPA to that of components of 
ECM, proenzymes and growth factors facilitates the interaction between the 
components and effective activation of plasminogen. tPA alone activates 
plasminogen at a very low rate. Binding of tPA to proteins of extracellular matrix, 
such as thrombospondin and collagen IV, increases the rate of plasminogen 
activation. Vascular smooth muscle cells (VSMCs), which are phenotypically 
similar to activated mesangial cells, produce the majority of tPA in vivo and 
express a tPA binding receptor which not only increases tPA activity but also 
decreases the inhibition of tPA by PAI-1 [62],
Administration of recombinant tPA provides a protective effect by 
decreasing glomerular matrix accumulation in an anti-Thyl model of glomerular 
matrix expansion [63], On the other hand, over-activation of tPA can produce 
harmful effects due to increased MMP activation and tubular basement 
membrane degradation [64]. Therefore it appears that tPA expression and 
activity have to be carefully regulated for normal functioning of renal tissue. 
uPA
Urokinase-type plasminogen activator (uPA), Mr of 55,000, having trypsin­
like protease activity, was first isolated from urine. Like tPA, uPA is also 
composed of domains that facilitate effective activation of plasminogen. Domains 
of uPA are homologous to those of EGF, plasminogen and trypsin-like protease.
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Many cell types express a cystein-rich 65 kDa receptor for uPA (u-PAR) 
[62], uPA binds to N-terminal domain of u-PAR with high affinity. Binding of uPA 
to uPAR initiates intracellular signal transduction and triggers local proteolysis by 
decreasing the Km for plasminogen activation by up to 200-300 fold, both of 
which play a critical role in tissue development. Activated plasmin in turn 
amplifies the fibrinolytic potential by activating zymogen pro-uPA. Thus an initial 
activation of small amounts of plasminogen can generate large amounts of 
plasmin through a positive feedback loop [62], Mice expressing an inducible uPA 
transgene or following administration of an adenoviral vector containing a uPA 
gene had reduced fibrosis [65].
Studies have shown that tPa and uPA are complimentary activators of 
plasminogen with a high degree of functional overlap. Conventionally, tPA 
regulates plasminogen activation in intravascular compartment, whereas uPA 
does so in tissues. [66], Also tPA plays a major role in fibrinolysis, whereas uPA 
has been associated with cell migration [67],
PAI-1
PAI-1 (Serpin E1) is a member of the SERPIN (SERine-Protease-lnhibitor) 
family of protease inhibitors [68]. It is a single-chain, 379 amino acid, 52-kDa 
glycoprotein (~13% carbohydrate) that exists in active, inactive and latent forms. 
The active form spontaneously converts to a latent form, which can be partially 
reactivated by denaturing agents [56], The reactive center of the inhibitor is 
contained within the exposed “strained loop region” at the carboxy terminal of the 
molecule. This serves as a pseudosubstrate for the target serine proteases.
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PAI-1 is not normally expressed in kidneys but is rapidly induced in a 
variety of pathological states. Newly synthesized PAI-1 is released into the 
extracellular space where it is converted into its inactive latent form in a few 
minutes. Binding of PAI-1 to matrix proteins such as vitronectin increases its half- 
life >10 times, thus enabling matrix the to resist proteolysis by invading cells [69], 
[25], Mesangial cells along with glomerular endothelial and epithelial cells have 
been identified as a source of PAI-1 expression under different conditions. [25, 
70, 71]. The major function of PAI-1 is to regulate extracellular matrix turnover by 
inhibiting the activation of proteases that break down the matrix. PAI-1 does so 
by forming a 1:1 stoichiometric reversible complex with tPA and uPA, thereby 
inhibiting them [56]. PAI-1-plasminogen activator complexes can be endocytosed 
and subsequently degraded by lysosomes, thereby providing a clearance 
mechanism for fibrolytic activity [69].
The inhibition of plasminogen activators by PAI-1 is the rate-limiting step 
in matrix degradation. Not surprisingly, increased PAI-1 expression has been 
associated with increased matrix deposition and tissue fibrosis. PAI-1 is nearly 
undetectable in normal kidneys by immunohistochemistry and in situ 
hybridization. However, increased PAI-1 expression is seen in many human and 
experimental glomerular diseases including acute (thrombotic microangiopathy, 
renal vasculitis, proliferative glomerulonephritis and membranous nephritis) and 
chronic human diseases (diabetic nephropathy, hypertensive nephropathy, focal 
segmental glomerulonephritis and lupus nephritis) and animal models in different 
renal cell types including mesangial cells [25]. Studies with knock-out mice
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clearly established the role of PAI-1 in fibrosis. PAI-1 knock out mice were 
resistant to renal injury caused by unilateral ureteral obstruction [71] and 
pulmonary fibrosis caused by bleomycin (an antineoplastic drug producing 
pulmonary fibrosis as a side effect) [72]. Similarly, PAI-1 knockout mice were 
protected against N-nitro-L-arginine methyl ester (L-NAME)-induced perivascular 
fibrosis [73]. Conversely, over expression of PAI-1 worsened bleomycin-induced 
fibrosis [72]. By virtue of its action on matrix turnover, PAI-1 also plays an 
important role in neointima formation, angiogenesis, atherosclerosis, tumor 
growth and metastasis, and wound healing. PAI-1 may play a role in cell 
adhesion and migration as a result of its high affinity binding to vitronectin.
PAI-1 acts as a gatekeeper guarding against fibrinolysis by inhibiting 
unnecessary activation of the plasminogen cascade. Hence it is one of the most 
highly regulated components of the plasminogen activation system. The human 
PAI-1 gene is located on the long arm of chromosome 7. It is comprised of nine 
exons and eight introns, and is ~12.2 kb long. Alternative polyadenylation of PAI- 
1 mRNA results in two distinct transcripts, one 2.8 kb long and the other 3.2 kb 
long. The PAI-1 gene and its flanking region contain 12 Alu repeat elements and 
5 long poly (Pur) repeat elements. Also, the promoter contains a 4G/5G 
polymorphism at -675. It is suggested that the presence of 4Gs in the promoter 
is associated with increased production of PAI-1 [74],
PAI-1 expression is induced by a variety of factors including growth 
factors, coagulation factors, metabolic factors and hormones such as 
transforming growth factor-(B (TGF(3), epidermal growth factor (EGF), fibroblast
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growth factor (FGF), fibrin fragments, thrombin, glucose, insulin, Angiotensin, 
hypoxia, glucocorticoids and radiation [25]. Regulation is primarily at the 
transcription level, although cyclic nucleotides may regulate PAI-1 message 
stability [25, 75]. The PAI-1 promoter has two AP-1 like sites, two SP-1 sites, 
three SMAD sites, one NF-kB site, glucocorticoid response elements (GRE) and 
hypoxia response elements (HRE) allowing the regulation of promoter by multiple 
pathways [76-79], Indeed, inflammatory mediators such as TGF(3, triglycerides, 
fatty acids and phorbol esters increase PAI-1 expression. PAI-1 expression is 
regulated by signal inputs from many intracellular signaling pathways including 
MAPK, Smad, PKA, PKC, nuclear receptors and Rho signaling [76, 80-84],
PAI-1, in turn, inhibits uPA-plasminogen activation, which normally 
activates latent TGFp, a major inducer of PAI-1 expression in mesenchymal cells. 
Thus TGFp turns off its own production through induction of PAI-1. The 
autoregulatory feedback loop between TGFp and PAI-1 plays an important role in 
wound healing and in limiting ECM deposition [69]. A detailed understanding of 
signal transduction involved in TGFp induced PAI-1 expression is required to 
identify potential targets for the intervention of TGFp mediated PAI-1 expression 
and fibrosis.
In a previous study we have shown that changes in actin cytoskeleton 
regulate a-SMA gene expression and hypertrophy in mesangial cells [28]. Like a- 
SMA expression and hypertrophy, de novo expression of PAI-1 is also seen with 
myofibroblast differentiation [85, 86], It is possible that regulation of both the 
genes share common or similar underlying regulatory mechanisms, suggesting
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regulation of PAI-1 by actin cytoskeleton. Also, recently Schnaper et al have 
shown that the inhibition of actin polymerization blocks TGFP-mediated collagen 
expression [87]. It is logical to think that changes in actin cytoskeleton may also 
similarly modulate expression of PAI-1, another TGFp-dependent gene and a 
regulator of ECM. Thus two independent lines of evidence suggest regulation of 
PAI-1 expression by changes in actin polymerization.
TGFp in Renal Diseases
Transforming Growth Factor-p (TGFp) regulates extracellular matrix 
production by increasing the production of matrix components such as collagen, 
fibronectin, laminin and heparan sulfate proteoglycans, and simultaneously 
decreasing matrix degradation by increasing production of plasminogen activator 
inhibitor-1 (PAI-1) [88]. The net result is an increase in extracellular matrix 
production and glomerulosclerosis [89, 90]. TGFp regulates a range of cellular 
processes including the cell cycle, differentiation, wound healing, extracellular 
matrix production and the immune response [91-94], TGFp circulates in an 
inactive form bound with latency-associated peptide (LAP) and is activated 
locally when LAP binds to integrin avp6 and TGFp is cleaved.
Not surprisingly, TGFp is present in human glomeruli in several 
glomerular diseases including diabetic nephropathy [95] and is associated with 
increased mesangial matrix production [96]. During pathogenesis of these renal 
diseases, TGFp signaling causes tubular atrophy, podocyte depletion, loss of 
capillary endothelial cells, mesangial cell activation and epithelial-to- 
mesenchymal transdifferentiation. The combination of these multiple pathogenic
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events leads to loss of functioning renal tissue [91]. The role of TGFp in renal 
fibrosis has also been proven in a variety of animal models [97, 98]. Integrin av|36 
knockout mice, which are unable to release LAP inhibition of TGFp, were 
protected against pulmonary fibrosis [99], Administration of anti-TGFp antibody 
protected against scarring in an animal model of chronic renal disease confirming 
the role of TGFp in fibrosis [100].
Rho and PAI-1 expression
Rho proteins regulate gene expression by increasing activity of 
transcription factors such as c-jun, ATF2a, ELK and STAT3 through intracellular 
signaling pathways such as MAPK and src [101]. Recently, the protective effects 
of Rho-kinase inhibitors against tissue fibrosis have established the role of Rho in 
the pathogenesis of tissue fibrosis. The Rho-kinase (ROCK) inhibitor Y-27632 
markedly decreased bleomycin-induced pulmonary fibrosis and collagen 
accumulation in mice [102], Similarly, Y-27632 protects against hepatic fibrosis 
[103]. The inhibition of Rho-kinase also protects against tubulointerstitial fibrosis 
in mouse kidneys with unilateral ureteral obstruction [104]. The basis for the 
protective effects of Rho-inhibition is not fully understood. Inhibition of expression 
of profibrotic molecules such as PAI-1 appears to be a potential mechanism. 
Inhibition of Rho by C3 exoenzyme decreases PAI-1 production in rat proximal 
tubules [105] and aortic endothelial cells [106]. Co-transfection with dominant 
negative RhoA decreases PAI-1 promoter activity, whereas constitutively-active 
RhoA increases PAI-1 in chicken atrial cells [107], ROCK inhibition blocks PAI-1 
expression in response to Angiotensin II. [108], Also, ROCK inhibition blocks
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PAI-1 promoter activity [81]. Thus, both inhibition of Rho activation and inhibition 
of signaling downstream of Rho lead to inhibition of PAI-1 expression. 
Collectively, these facts suggest that inhibition of Rho protects against fibrosis 
through inhibition of PAI-1.
Although the role of Rho in the regulation of PAI-1 expression is becoming 
increasingly clear, the mechanism for this effect has not been examined. Since 
actin polymerization is one of the major functions of Rho-ROCK signaling (Fig.
3), it is plausible that the effect of Rho-inhibition is mediated by depolymerization 
of actin. Taken together, these observations suggest that Rho-mediated 
changes in actin cytoskeletal structure modulate PAI-1 expression. Given the 
diversity of signaling pathways that interact with Rho, it is possible that Rho 
mediates and integrates the effect of these pathways on PAI-1 expression by 
modulating actin cytoskeleton organization.
Hypothesis and aims
The Central hypothesis is that changes in actin polymerization regulate 
the myofibroblast-like phenotype of kidney mesangial cells by simultaneously 
regulating expression of multiple genes.
The overall objective is to characterize the mechanisms of mesangial 
myofibroblast-like differentiation.
The working hypothesis is that Rho-mediated changes in actin 
cytoskeletal structure modulate PAI-1 expression in glomerular mesangial cells.
My specific aims are to examine the role of Rho in the regulation of TGF[3- 
induced PAI-1 expression in human mesangial cells as follows:
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Specific Aim 1:
Specific Aim 2: 
Specific Aim 3:
Specific Aim 4:
Specific Aim 5:
To profile the effects of actin cytoskeleton on the expression 
of multiple genes in human mesangial cells.
To examine the effect of TGFp on PAI-1 expression 
To examine the role of Rho and actin cytoskeleton in TGFp- 
induced PAI-1 expression.
To examine the role of Rho and actin cytoskeleton in TGFp- 
induced PAI-1 promoter.
To examine the effect of TGFp and actin cytoskeleton on 
plasminogen activators.
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CHAPTER 2 
MATERIALS AND METHODS 
Cell culture
Human mesangial cells (HMCs) were cultured in RPMI 1640 (Mediatech 
Inc., Herndon, VA) with 16.7% fetal bovine serum (Invitrogen, Carlsbad, CA). 
from renal glomeruli isolated by the sieving method. HMCs between passages 5 
and 9 (P5 -P9) were used for experiments. After plating in serum-containing 
media, cells were serum-starved at 60-80% confluence. After 24 hours of serum 
starvation, cells were pre-treated with agents that depolymerize (Cytochalasin B:
1.0 nM, Latrunculin B: 0.1 pM, Toxin B: 10 pM, Y-27632: 10 pM, HA-1077: 20 
pM) and/or stabilize actin cytoskeleton (Jasplakinolide: 50 nM) for one hour prior 
to addition of 10 ng/ml TGFp for the indicated time periods. Cytochalasin B was 
purchased from Sigma Chemical Co., St. Louis, MO. The Rho-kinase inhibitor, Y- 
27632, was purchased from Welfide Corporation, Osaka, Japan. Another Rho- 
kinase inhibitor, HA-1077, was purchased from AG Scientific Inc., San Diego,
CA. Clostridium Difficile Toxin B (Toxin B), Latrunculin B (LatB) and 
Jasplakinolide (Jas) were purchased from Calbiochem, San Diego, CA. Human 
recombinant TGFp was purchased from R&D Systems, Minneapolis, MN.
DNA Array Analysis
The RNA isolation, DNAse treatment, Poly A+ enrichment, cDNA probe 
synthesis, hybridization and analysis of scanned arrays were performed as per 
manufacturer’s protocol [109],
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RNA Isolation
Human mesangial cells were plated on five 10 cm dishes per condition. At 
the end of the desired treatment, cells were trypsinized and spun down at 680xg 
for 5 minutes. The pellet was resuspended in 1 ml denaturing buffer. A 0.5 ml 
aliquot was transferred to sterile 1.5 ml tube and incubated on ice for 5-10 min. 
After vortexing briefly, the homogenate was centrifuged at 13,370xg for 15 min at 
4°C to remove cellular debris. The supernatant was transferred to a new 2 ml 
tube and 1 ml of Tris-EDTA saturated phenol was added to it. The tube was 
vortexed for 1 min. After a 5 min incubation on ice, 0.3 ml chloroform was added. 
The sample was vortexed vigorously for 1-2 min and then incubated on ice for 5 
min. The homogenate was centrifuged at 13,370xg for 10 min at 4°C. The upper 
aqueous phase containing RNA was transferred to a new 2 ml tube. A second 
round of phenol chloroform extraction using 0.8 ml saturated phenol and 0.3 ml 
chloroform was performed. Next, 1 ml isopropanol was added with incubation on 
ice for 10 min. The samples were centrifuged at 13,370xg for 15 min at 4°C. The 
pellet was washed with 0.5 ml of 80% ethanol. The samples were centrifuged at 
13,370xg for 15 min at 4°C. The supernatant was discarded and the pellet was 
air-dried. The pellet was re-suspended in 25 pi RNase-free H20.
DNase Treatment of Total RNA
The DNAse treatment reaction was set up in a final volume of 200 pi 
containing 100 pg total RNA, DNase (1 unit/pl) and 10 x DNase buffer (400 mM 
Tris-HCI (pH 7.5), 100 mM NaCI, 60 mM MgCh). After a 30 min incubation at 
37°C, the reaction was stopped by adding 20 pi termination mix (0.1 M EDTA (pH
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8.0), 1 mg/ml glycogen). The reaction was split into two 1.5 ml tubes. To each 
tube, 100 pi of saturated phenol and 60 pi chloroform were added followed by 
centrifugation at 16,170xg for 10 min at 4°C to separate phases. Top aqueous 
layer was carefully removed and placed in a 2.0 ml tube. To each tube, 1/10 
volume of 2 M (10 pi) NaOAc and 2.5 volumes (0.3 ml) of 95% ethanol were 
added. The mixtures were vortexed thoroughly and incubated on ice for 10 min. 
The tubes were centrifuged in a microfuge tube at 16,170xg for 15 min at 4°C. 
The pellets were washed with 100 pi of 80% ethanol followed by centrifugation at 
16,170xg for 5 min at 4°C. The supernatant was removed and the pellet was air- 
dried. The pellets were dissolved in 50 pi RNase-free H20.
Poly A+ RNA Enrichment and Probe Synthesis 
Streptavidin Magnetic Bead Preparation
Magnetic beads were re-suspended by inverting and gently tapping the 
tube. Aliquots containing 15 pi of beads per probe synthesis reaction were 
transferred into 0.5 ml tubes. Beads were separated on magnetic particle 
separator. The supernatant was pipetted off and discarded. Beads were washed 
with 150 pi of 1x binding buffer [109] and separated again on a magnetic particle 
separator. The supernatant was pipetted off and discarded. The cycle was 
repeated three times. The beads were resuspended in 15 pi 1x binding buffer per 
reaction.
Poly A+ RNA Enrichment
The PCR thermal cycler was preheated to 70°C. Aliquots of 10-50 pg total 
RNA were transferred into 0.5 ml tubes. Deionized H20  was added to make up a
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final volume of 45 jj.1. To each tube, 1 pi Biotinylated Oligo (dT) was added 
followed by incubation at 70°C for 2 min in the preheated thermal cycler. The 
reaction was cooled at room temperature for 10 min. To each tube, 45 pi 2x 
binding buffer was added. The washed beads were resuspended by pipetting up 
and down. Fifteen pi of beads were added to each RNA sample and mixed on a 
vortexer or shaker for 30 min at room temperature. Beads were separated using 
the magnetic separator. The supernatant was pipetted off and discarded. Beads 
were resuspended in 50 ul 1x wash buffer. Beads were again separated and 
washed once. Beads were resuspended in 6 pi dH20. 
cDNA Probe Synthesis
A master mix containing 5X reaction buffer (250 mM Tris-HCI (pH 8.3),
375 mM KCI, 15 mM MgCh), 10x dNTP mix (5 mM each dCTP, dGTP, dTTP), [a- 
32P] dATP (3000 Ci/mmol, 10 pCi/pl, 5 pl/reaction) and 10 mM DTT was 
prepared. One pi cDNA synthesis primer mix [109] was added to the 
resuspended beads. The beads and primer mix were incubated in the preheated 
thermal cycler at 65°C for 2 min. Meanwhile, 2 pi MMLV reverse transcriptase 
per reaction was added to master mix. To each reaction tube, 13.5 pi master mix 
was added followed by thorough mixing. Tubes were incubated at 50°C for 25 
min. The reactions were stopped by adding 2 pi 10x termination mix (0.1 M 
EDTA [pH 8.0], 1 mg/ml glycogen).
Column Chromatography
The probe synthesis reaction mixture was diluted to a final volume of 200 
pi with Buffer NT2 [109]. The sample was added to a NucleoSpin Extraction Spin
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Column and centrifuged at 16,170xg for 1 min. The NucleoSpin column was 
inserted into a fresh 2-ml collection tube and 400 pi Buffer NT3 [109] was added 
to the column. After centrifugation at 16,170xg for 1 min, the collection tube and 
the flow-through were discarded. The wash with Buffer NT3 was repeated twice. 
The NucleoSpin column to was transferred to a clean 1.5-ml microcentrifuge 
tube. One hundred pi of Buffer NE [109] was added to the column for 2 min 
followed by centrifugation at 16,170xg for 1 min to elute purified probe. The 
radioactivity of the probe was checked by scintillation counting.
Hybridization Procedure
The hybridization solution (BD ExpressHyb + sheared salmon testes DNA 
heated at 95°C for 5 min) was prewarmed at 68°C. The membrane was 
prehybridized for 30 min with continuous agitation at 68°C. To prepare the probe 
for hybridization, 5 pi Cot-1 DNA [109] was added to the entire pool of labeled 
probe followed by incubation in a boiling (95-100°C) water bath for 2 min. Next, 
the probe was incubated on ice for 2 min. The probe was added to the 
membrane and hybridized overnight with continuous agitation at 68°C.
The next day, the array membrane was washed with continuous agitation 
at 68°C with Wash Solution 1 (2X SSC, 1% SDS; 3 X30 min washes) and Wash 
Solution 2 (0.1X SSC, 0.5% SDS; 1X 30 min wash). The final 5-min wash was 
performed in 200 ml of 2X SSC with agitation at room temperature. The blot was 
wrapped with plastic and exposed to phosphorimager plates at room 
temperature.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
31
Analysis
The phosphor imager plates were scanned after a 3 day exposure to 
radio-active blots. Atlas Image software (Clontech, Palo Alto, CA) was used to 
analyze the scanned blots. According to manufacturer’s instructions, the signals 
from cDNA spots were normalized to a panel of three house-keeping genes 
(GAPDH, cytoplasmic [3-actin, 60S ribosomal protein L13A) on the same blot. 
The software takes into account the changes in the level of multiple house­
keeping genes and corrects the test gene signals accordingly. This provides a 
more accurate normalization of test genes as compared to using a single house­
keeping gene for normalization. Three housekeeping genes that were relatively 
unaffected by the treatment were selected to increase the accuracy of 
normalization. The ratios of normalized gene-expression values for CytB treated 
and untreated control were prepared. Arbitrarily, either more than a 2-fold 
increase or more than 50% inhibition in gene-expression were considered 
significant. The genes that failed to show a signal in either of the blots or showed 
a near-background signal were excluded from the analysis.
Western blot analysis
Western blot analysis was performed using alkaline phosphatase or 
enhanced chemiluminescence detection as described below.
Electrophoresis
Since PAI-1 is secreted upon synthesis, conditioned media in which the 
cells were cultured was used to detect changes in PAI-1 protein. Equal amounts 
of conditioned media were analyzed. After a 1:10 dilution of conditioned media in
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1X sample buffer (0.12M Tris 1.51 g, 2% SDS, 10% glycerol, pH 6.8), 20 pi of 
diluted samples per lane were electrophoresed on reducing polyacrylamide gels 
at 4°C. Proteins were separated first on 4% stack gel at 50 V for 30 min and 
then on 11 % resolving gel at 200 V for 90 min. The gels were run in tank buffer 
(Tris: 3.04 g/l, Glycine 14.4 g/l, SDS 1 g/l) at4°C. An HRP-labeled molecular 
weight marker, MagicMark (Invitrogen, Carlsbad, CA) was run on each gel along 
with the samples. The samples were transferred onto PVDF overnight at 15 V in 
cooled (4°C) Western blot buffer (Tris 3 g/l, Glycine 14.5 g/l, methanol 20%). 
Immunodetection 
Alkaline-Phosphatase Detection
After overnight transfer, membranes were washed five times with dH20 to 
remove excess methanol. Membranes were blocked overnight with 5% milk in 
high salt-TBS (Tris 20 mM, NaCI 500 mM). After two 10-min washes with TBS- 
Tween (Tris 20 mM, NaCI 500 mM, Tween 20 0.05%, pH 7.5), membranes were 
incubated one hour each at room temperature, first with goat anti-PAI-1 antibody 
(American diagnostica, Stamford, CT) diluted 1:500 in TBS/Tween and then with 
a biotinylated secondary anti-goat antibody (Pierce, Rockford, IL) diluted 1:500 in 
TBS-Tween. Between and after incubations with antibodies, membranes were 
washed four times for 15 min each with TBS-Tween. After washing, PAI-1 
antigen was detected using the Vectastain ABC system (Vector laboratories, 
Burlingame, CA). Blots were incubated for one hour with Vectastain ABC reagent 
for alkalaline phosphatase detection. Blots were washed twice for 15 min each 
wash with high salt TBS-Tween and once for 15 min with high salt TBS. After
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briefly washing membranes with BCIP-NBT buffer (Tris 0.1 M, MgCI2 0.5 mM, pH
9.5), BCIP-NBT detection reagent (Bromo Chloro Indolyl Phosphate-Nitrozolium 
Blue in BCIP-NBT buffer) was added to the membrane. After a sufficient amount 
of signal was obtained, blots were washed with dH20  and air-dried.
Enhanced Chemiluminescence Detection
After overnight transfer, membranes were washed five times with dH20  to 
remove excess methanol. Membranes were blocked for one hour with NAP-Sure 
Blocker (Geno Technology, St. Louis, MO). Membranes were incubated one hour 
each at room temperature, first with Goat Anti-PAI-1 antibody (American 
diagnostica, Stamford, CT) diluted 1:1000 in TBS/Tween and then with horse 
raddish peroxidase (HRP)-labeled secondary anti-goat antibody (Jackson 
Immunoresearch, West Grove, PA) diluted 1:20,000 in TBS/Tween. Anti-tPA 
antibody (PAM-3 clone, American diagnostics, Stamford, CT) was used at 1:200 
dilution and anti-uPa antibody (American diagnostics, Stamford, CT) was used at 
1:1000 dilution. HRP-labeled secondary antibodies were used at 1:20,000 
dilution. Between blocking and incubations with antibodies, membranes were 
washed once for 15 min and twice for 5 min with TBS/tween ( Tris 20 mM, NaCI 
500 mM, Tween 20 0.05%, pH 7.5) At the end of the incubation with the 
secondary antibody, membranes were washed once for 15 min and four times for 
5 min with TBS/Tween. Substrate buffer from Enhanced Chemiluminescence 
Western blotting analysis system (Amersham Biosciences, Piscataway, NJ) was 
added to the blots for one minute to detect HRP-signal on the membrane. X-ray
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films were exposed to the blot for varying amounts of time to detect optimum 
signal from the blot.
Analysis
X-ray films were scanned on a flatbed scanner with a transparency 
adapter and analyzed using NIH Image software, available on the internet at 
http://rsb.info.nih.gov/nih-image/Default.html (National Institute of Health, 
Bethesda, MD).
Northern Blot Analysis
Northern blot analysis for PAI-1 mRNA was performed using partial a PAI- 
1 cDNA as probe (Clontech, Palo Alto, CA).
Electrophoresis
Ten pg total mRNA was incubated with 5.4 pi 6M glyoxal, 16 pi DMSO,
3.0 pi 0.1 M Sodium Phosphate at 50°C in heat block for 1 hr. Samples were 
cooled to 0°C on ice. After adding 4 pi loading dye, samples were run on a 1.2 % 
agarose gel with ethidium bromide in running buffer (1.9 ml 1M NaH2P04, 6.1 ml 
1M Na2HP04,990 ml DEPC H20) at 50 V for 30 min to allow all the samples to 
migrate out of the well and into the gel. Next, the gel was run at 75 V for 
approximately 3 hours with buffer circulation. A digital photograph of the gel was 
taken using Eagle Eye II (Stratagene, LA Jolla, CA) under UV light to document 
18S/28S loading in each lane. RNA was transferred onto positively-charged 
nylon membrane (Roche, Indianapolis, IN) overnight in 1X TAE (Tris 4.84 g/l, 
Glacial Acetic Acid 1.14 g/l, EDTA 0.744) at 25 V and 4°C.
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UV Cross linking
After overnight transfer, the membranes were air dried for 10 min. RNA 
was cross-linked to membranes using UV cross-linker 1800 (Stratagene, LA 
Jolla, CA) at 120 m Joules. Hybridization was then performed or the membrane 
was stored at -20°C for probing at a later time.
Hybridization
The blots were incubated at 42°C for 1 hr to overnight in pre-hybridization 
solution (5%Formamide, 5X SSPE, 5XDenhardt’s, 0.1 mg/ml Salmon Testes 
DNA, 0.5% SDS) in a Techne Hybridizer HB-2D hybridization oven (Burlington, 
NJ). After sufficient pre-hybridization, 25-50 ng/ 2 pi PAI-1 cDNA probe (0.5 pi in 
case of 18S fragment) (Clontech, Mountain View, CA) was brought up to 15 pi 
using DEPC H20. Probe was denatured in boiling H20 for 15 min. While probe 
was denaturing, the following reagents from Random Primer DNA Labeling 
System ( Invitrogen, Carlsbad, CA) were combined in a final volume of 49 pi on 
ice: 2 pi dATP, 2 pi dGTP, 2 pi dTTP, random primer buffer solution (0.67 M 
HEPES, 0.17 M Tris-HCI, 17 mM MgCI2, 33 mM 2-mercaptoethanol, 1.33 mg/ml 
BSA, 18 OD260 units/ml oligodeoxyribonucleotide primers, pH 6.8), 32P-dCTP 
(approximately 50 pCi or 20pCi for the 18S probe). The denatured probe was 
immediately transferred to ice and the probe added to the preassembled labeling 
mix. To the probe mix, 1 pi Klenow fragment (3U/pl) was added and mixed 
gently. Probe synthesis was allowed at 37°C for 30 min and then stopped with 5 
pi stop buffer (0.5 M EDTA, pH 8.0). Radio-labeled probe was denatured by
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boiling at 100°C for at least 10 min. While the probe was being labeled, the pre­
hybridization solution was replaced by 10 ml hybridization solution per blot (50% 
Formamide, 5X SSPE (NaCI 43.8 g/l, Na phosphate (mono) 6.9, EDTA 1.9 g/l, 
pH 7.4), 5X Denhardt’s (Ficoll 1 g/l, polyvinylpyrrolidone 1 g/l, BSA 1 g/l), 0.11 
mg/ml Salmon Testes DNA, 0.5% SDS, 4% Dextran Sulfate). Radio-labeled 
probe was carefully added to the tube and the probe was hybridized with the blot 
in hybridization oven overnight at 42°C.
Washing
After overnight hybridization, blots were washed twice for 10 min each with 100 
ml 5X SSPE (NaCI 43.8 g/l, Na phosphate (mono) 6.9, EDTA 1.9 g/l, pH 7.4) and 
0.5 % SDS to remove non-specific binding. Blots were washed for 5 min at 65°C 
in 0.5% SSPE and 1% SDS. If the blots were still radioactive at the edges, an 
additional wash with 0.1X SSPE and 1% SDS was performed for 5 min at 65°C. 
The blots were wrapped in saran wrap and exposed to a phosphor-imaging 
cassette (Molecular Dynamics-Amersham, Piscataway, NJ). For PAI-1 mRNA 
detection, the phosphorimager plates were scanned after 2-3 days.
The membranes were stripped before probing for 18S. The blots were 
washed in 50-100 ml nearly boiling DEPC H20 for 15 min 2-3 times.
18S Hybridization
The membranes were probed with radio-labeled 18S fragment using the 
Northern blot protocol described above. The blots were exposed to phosphor 
imager plates for 30 min to few hours.
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Analysis
The blots were scanned using phosphor imager scanner. The densitometric 
analysis for PAI-1 bands was performed using Image Quant Software (Molecular 
Dynamics-Amersham, Piscataway, NJ).
Immunocytochemistry
Adherent cells on coverslips were immunofluorescently stained using a 
two-day protocol. For PAI-1 staining, cells were plated on serum-coated dishes in 
serum-free media.
At the end of desired period of treatment, cells were washed 3 times with 
2 ml Hank’s balanced salt solution. Cells were fixed with 2 ml 3.7% 
paraformaldehyde in PBS ( monobasic sodium phosphate 0.5 g/l, dibasic sodium 
phosphate 2.3 g/l, NaCI 8.5 g/l) at room temperature for 10 min. 
Paraformaldehyde was washed off with 3x 2 ml washes with TBS. Cells were 
permeabilized with 2 ml 0.5% Triton X-100 in TBS (Tris 25 mM, NaCI 0.9%, pH
7.5) for 5 min at room temperature, after which they were washed 3x with 2 ml 
TBS. Cells were incubated with 5% blocking milk (centrifuged at 13,370 G for 1 
hour) in TBS for at least one hour at room temperature. Coverslips were 
incubated with primary goat anti-PAI-1 antibody diluted 1:100 in milk-TBS 
overnight at 4°C in a humidified chamber.
After overnight incubation, coverslips were washed 1x with milk and 2x 
with TBS for 10 min each. Coverslips were incubated with secondary antibody 
Biotinylated anti-Goat diluted 1:100 in milk-TBS for 2 hr at 37°C in a humidified 
box. Excess antibody was washed off once with milk and twice with TBS for 10
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min each. Coverslips were incubated with mixture of FITC-avidin and Texas red 
phalloidin diluted 1:200 in TBS at 37°C for 1 hr. Cells were washed 3x with TBS 
briefly and then once with 1 i^M TBS-Biotin (10 ml TB S /1 00jj.I 1mM biotin).
Finally after washing once with dH20, excess water was drained off. Coverslips 
were air dried and mounted on glass slide with 25 (j,l gelvatol.
Images were captured using a Spot digital camera attached to a 
fluorescent microscope.
Quantitative Real-time Polymerase Chain Reaction (PCR)
Principle of Quantitative real-time PCR
In real-time PCR, amplification of DNA is monitored during each cycle 
allowing accurate quantitative estimation of nucleic acid concentration. The cycle 
number at which the signal starts to increase exponentially over the background 
is called the crossover point. Comparison of crossover points of samples with 
those of known concentrations of standard cDNAs gives the concentration of a 
particular template in the sample. Relative quantification with external standards 
as a method for comparing gene expression was used in this study. In this 
method of quantification, a reference, typically a house-keeping, gene is used to 
normalize the concentration of the target gene. First, the concentrations of target 
and reference genes are obtained by using an external standard curve of known 
amounts of nucleic acid. The results are expressed as target/reference ratio. The 
use of an endogenous control, corrects for the factors affecting PCR efficiency. 
Following is the protocol used in this study.
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RNA Isolation and Quantification
Total cellular RNA was isolated using TRIzol method as described earlier 
and quantified using a UV spectrophotometer.
DNAse treatment
The protocol for real time PCR analysis was modified from a previous 
protocol [110]. Briefly, 1 pg total RNA sample was DNAse treated and 
subsequently reverse transcribed using specific anti-sense primers for PAI-1 and 
Ubiquitin (UBC, reference gene) in the same reaction (Table 2). In a typical 
reaction, a total of 4 pg mRNA was treated with 4 pi of 1 U/pl DNAse I 
(Invitrogen, Carlsbad, CA) in the presence of 2 pl of 10 x reaction buffer in a total 
reaction volume of 20 pl. After a 15-minute incubation at room temperature, 
DNAse treatment was stopped by incubating the mixture at 65° C for 10 min with 
2 pl of 25 mM EDTA. DNAse-treated total RNA was stored at -80° C until further 
use in the reverse transcription (RT) reaction.
RT reaction
DNAse treated mRNA was reverse-transcribed using a thermocycler (MJ 
Research, Reno, NV). The test gene and housekeeping gene were reverse- 
transcribed simultaneously using their specific anti-sense primers in the same 
reaction. Performing RT for both genes, the gene of interest and the reference 
gene, in the same reaction minimizes the error due to the efficiency of the RT 
reaction and hence provides a good way of normalizing for a reference gene in 
the RT reaction. 1 pg of DNAse treated RNA (1 pg/5 pl) was reverse transcribed 
in a final reaction volume of 25 pl. The reaction mix also contained RT buffer
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(Promega, Madison, Wl), 60 U RNAse inhibitor, 3 pM anti-sense primer for 
sample gene, 3 pM anti-sense primer for Ubiquitin, 10 pM DTT and 500 pM 
dNTPs. Reverse transcription reaction was performed at 37°C for one hour in a 
thermocycler followed by heat inactivation of the enzyme at 70°C for 10 min. RT 
products were immediately used for real-time PCR analysis on the Roche 
lightcycler PCR instrument.
Preparation of cDNA standards for real time PCR
The standards for the quantification were prepared as described 
previously [110], by amplifying 10-fold serial dilutions of known concentrations of 
templates for each gene. Briefly, cDNA was prepared for each gene from 1 pg 
human mesangial cell total RNA using specific anti-sense primers and amplified 
using a PCR reaction for 35 cycles. PCR products from 5 identical reactions for 
the same gene were pooled in a single tube. An aliquot of PCR products was run 
on 8% acrylamide to confirm the product size. PCR products were purified using 
“High pure PCR products purification kit” (Roche Diagnostics, Indianapolis, IN). 
The concentration of purified PCR products was measured using picoGREEN 
dsDNA quantification kit (Molecular probes, Eugene OR) [111]. Briefly, a 2 pg/ml 
stock solution of lambda dsDNA standard was prepared in TE (10 mM Tris-HCI, 
2 mM EDTA, pH 7.5). The stock solution was diluted in duplicate vials with TE to 
provide 0, 1.25, 2.5, 6.25, 12.5, 18.75 and 25 pg/pl concentration of standard. 
Duplicate vials containing 1 jal or 2 pl of test sample in a final volume of 1000 pl 
TE were prepared. To each vial 1 ml of PicoGreen dsDNA quantitation reagent 
[111] was added for 5 min. The vials were incubated in dark. After incubation,
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fluorescence from the standards and the samples were measured using a 
fluorometer using an excitation wavelength of 480 nm and emission wavelength 
of 520 nm. The values for standard concentrations were plotted on a graph. The 
concentration values for samples (pig/pil) were derived using the linear graph 
equation.
After fluorometric measurement, the concentration of purified product was 
adjusted to 5000 pg/pl. Ten-fold serial dilutions of PCR products were prepared 
to cover a range from 0.001 pg to 1 ng for the standard curve. These serial 
dilutions were amplified on lightcycler using specific parameters for each gene. 
Melting curve analysis was performed at the end of the PCR run to ensure the 
purity of the product and to eliminate the possibility of primer-dimers. Roche 
Lightcycler software was used to prepare a standard curve. The identities of 
PAI-1 and ubiquitin cDNAs were confirmed by sequencing (Midland Sequencing, 
Midland, TX)
Real-time PCR
After diluting RT products 1:10 in dH20, 2 pl of diluted sample was 
amplified using the LightCycler (Roche, Indianapolis, IN). Each gene of interest 
and the reference gene were analyzed in separate glass capillaries. The 
reactions were set up in the capillaries in a final volume of 20 pl, which contained 
2 pl of standard or diluted sample, MgCL (4 mM for PAI-1 or uPA, 1 mM for tPA), 
1 pM each of both the primers (table 2) and 10 pl of 2x SYBR green PCR mix 
(Qiagen, Valencia, CA). The hot start method was used to initiate PCR reaction
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Table 2. Primer sequences for real-time PCR analysis
Gene Sense Primer (5’-3’) Anti-Sense Primer (5’-3’)
PAI-1 TGCTGGTGAATGCCCTCTACT CGGTCATTCCCAGGTTCTCTA
UBC ATTTGGGTCGCGGTTCTTG TGCCTT GACATT CT CGAT GGT
TPA CCCCAGGCAAACTTGCAC GCCTTT GCAGT GT CTT CT GAA
uPA CACGCAAGGGGAGATGAA ACAGCATTTTGGT GGT GACTT
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by heating the samples at 95° C for 15 min prior to PCR cycling. The following 
cycling parameters were used for the amplification: denaturation at 95° C for 15 
s, annealing at 60° C (PAI-1, uPA) or at 56° C (tPA) for 5 s, and extension at 72° 
C for 18 s. Samples were amplified for 35 (PAI-1, tPA) or 40 cycles (uPA). Gene 
amplification was monitored in real-time with SYBR green dye. The crossing 
points of sample genes were compared against the crossing points of known 
standards to determine the absolute concentration of a gene in a particular 
sample. Values for the gene of interest were normalized to Ubiquitin amplified 
from the same sample. At the end of PCR cycling, the melting curve of the 
products was analyzed to ensure the specificity of the reaction. PCR products 
from representative experiments were run on the gel and visualized by ethidium 
bromide staining to further ensure the specificity of the reaction.
Table 2 shows the primers used for real-time PCR analysis of PAI-1, tPA, 
uPA and Ubiquitin. The primers for PAI-1, uPA and Ubiquitin were purchased 
from a commercial vendor (Midland Reagents, Midland, TX) using previously 
published primer sequences [110]. The protocol for tPA detection was developed 
in our lab using the primers designed and synthesized by TIB Molbiol LLC 
(Adelphia, NJ).
Melting curve analysis
Melting curve analysis was performed at the end of each run to ensure 
specific amplification of a single product in three steps:
a. Rapid heating to 95°C to denature all the DNA present in the mixture
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
44
b. Cooling to below annealing temperature to allow formation of double 
stranded DNA.
c. Gradual heating to 95°C to melt double stranded DNA
Melting curve analysis showed a single peak suggesting a pure population 
of PAI-1, tPA, uPA and UBC cDNA in PCR products. The PCR products were run 
on a gel to confirm the size of the product and to detect the purity of the reaction. 
Subsequently, products from representative experiments were run on a gel to 
ensure amplification of single template of expected size.
Cloning of PAI-1 promoter 
PCR cloning of the promoter
The PAI-1 promoter containing major regulatory elements as listed in chapter 6 
was cloned from human mesangial cells using specific primers. Human genomic 
DNA was isolated from primary culture human mesangial cells using a DNA 
isolation kit (Clontech, Palo Alto, CA). Primers for a 1106 bp promoter (- 973 to 
+133) were purchased from a commercial vendor (Midland Reagents, Minland, 
TX) as published by Grenette et al [112].
Forward primer: 5’-CGATCGGTACCTAAAAGCACACCCTGCAAAC-3’
Reverse primer: 5’-CGATCAGATCTCAGAGGTGCCTTGCGATTG-3’
A total of three reactions were set up with 2 pg genomic DNA, 4 pg DNA or no 
DNA. The reactions were set up in a 100 pl reaction mix containing 150 pmol of 
sense and anti-sense primers, 1.5 mM MgC^and 1 pl platinum taq polymerase. 
PCR reaction was performed for 30 cycles using the following parameters:
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denaturation at 94°C for 45 seconds, primer annealing at 58°C for 45 seconds 
and primer extension at 72°C for 45 seconds. An additional 5-min incubation at 
72°C was performed to complete the reaction. PCR products from all three 
reactions were run on a 1% agarose gel in TAE buffer (Tris 4.84 g/l, Glacial 
Acetic Acid 1.14 g/l, EDTA 0.74 g/l) to ensure the product size. Bands were seen 
at the expected sizes of 1100 bp. No bands were seen in the negative control, 
which contained no DNA.
Ligation
Next, pGL3 basic vector (restriction sites at 5 and 36) and PCR products 
(restriction sites in cloning primers) were cut with Kpnl and Bgl II restriction 
enzymes. Digested fragments were cleaned with geneclean spin kit (Qbiogene, 
Carlsbad, CA). The approximate concentration of digested fragments was 
determined by comparing the densities of bands with the density of ladder.
Sticky ends of PAI-1 promoter were ligated into pGL3 basic vector at an insert: 
vector ratio of 1:3 using either 2 pl or 4 pl DNA ligase (1 U/pl) in a final volume of 
15 pl at room temperature overnight. Top 10 competent E. coli were transformed 
with pGL3 vectors to select the plasmid containing the PAI-1 promoter. The 
transformed Top 10 competent cells were grown on ampicillin plates overnight. 
Representative colonies of bacteria were inoculated into 10 ml of LB media 
(Bacto-tryptone 10 g, Bacto-yeast extract 5 g, NaCI 5 g, dH20  1 L, pH 7.0) 
containing 125 pg/ml ampicillin and incubated overnight at 37°C with vigorous 
shaking. The tubes were incubated on ice for 30 minutes. Bacteria were 
harvested by centrifugation at 1540 G for 15 min at 4° C. The pellet was washed
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in 1 ml ice-cold STE buffer (100 mM NaCI, 10 mM Tris, 1 mM EDTA, pH 8.0) 
followed by centrifugation at 281 Oxg for 15 min at 4°C. The pellet was 
resuspended in 300 pl of Buffer P1 (50 mM Tris, 10 mM EDTA, pH 8.0). Next,
300 pl of Buffer P2 (200 mM NaOH, 1 % SDS) was added with gentle mixing. 
Finally, 300 pl Buffer P3 (2.55 M Potassium Acetate adjusted to pH to 4.8 with 
acetic acid) was added with gentle mixing. The tubes were centrifuged at 
15,000xg for 15 min at 4° C. The supernatant was transferred to a fresh, sterile 
microfuge tube. Plasmid DNA was precipitated by incubation with 800 pl of 100% 
isopropanol at room temperature for 30 minutes. The tubes were centrifuged at 
16,000 G for 10 min at 20° C. The pellet was washed twice with 70% ethanol 
followed by centrifugation at 16,000xg for 10 min at 20°C. The pellet was dried 
under vacuum and resuspended in 100 pl of sterile dH20  containing 1 pl of 
RNAse A (1 pg/pl). The plasmid concentration was measured by measuring 
260/280 absorbance with a UV spectrophotometer.
A restriction enzyme digest of the isolated plasmid with Kpnl and Bglll was 
set up to ensure that the isolated plasmid contained the desired PAI-1 promoter. 
The digested products were run on the gel. The preparation that showed a band 
corresponding to expected size of PAI-1 promoter (1106 bp) was presumed to be 
the successful cloning of PAI-1 promoter. Sequencing of the insert in this plasmid 
confirmed successful cloning of 1100 bp human PAI-1 promoter in pGL3 basic 
vector.
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Transient Transfection
Human and rat mesangial cells were co-transfected with 1 jjg pGL3 vector 
containing PAI-1 promoter and 1 pg renilla luciferase vector per well (control for 
transfection efficiency). Control cells were co-transfected with empty pGL3 basic 
vector and renilla luciferase vectors. Fugene 6 (Roche, Indianapolis, IN) was 
used to transfect cells in 6-well pates with PAI-1 promoter. Cells were transfected 
at 60-80% confluence with 1 pg PAI-1 promoter-containing plasmid and 1 pg 
renilla luciferase plasmid. The cells were serum-starved at the time of 
transfection. First, 4 pl Fugene 6 per pg DNA was incubated with 100 pl serum- 
free media/well for 15 minutes. Next, 2 pg DNA/well was added to the tube. The 
resulting transfection mixture was incubated at room temperature for 30 min. 
Meanwhile, the cells were washed and the media was changed to 1 ml fresh 
serum-free media. To each well 100 pl Fugene-DNA complexes were added 
drop wise. After three hours of transfection, CytB was added to appropriate wells. 
After 24 hours, cells were treated with 10 ng/ml TGF(3 for 6 hours.
Luciferase Reporter Assay
Upon completion of the experiments, transfected cells were washed 3 
times with ice-cold PBS and 150 pl 1X passive lysis buffer (Promega, Madison, 
Wl) was added to each well. Plates were wrapped in Parafilm and frozen at 
-80°C for at least 1 hour. Cells were scraped after thawing the plates at room 
temperature for 3 min. Lysates were centrifuged at 13,370xg for 1 min at 4°C to 
remove cellular debris. After equilibrating to room temperature, 20 pl of 
supernatant was added quickly to 100 pl of reporter assay reagent containing
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firefly luciferase substrate. Luciferase activity was measured by using TD 20/20 
luminometer (Turner Diagnostics, Sunnyvale, CA) set for dual luciferase 
detection mode. The sensitivity of the detection was maintained at 
manufacturer’s default level (50.9%) for all the assays. The samples were read 
after a delay of 2 seconds to allow luciferase activity to begin. The samples were 
read for a total of 15 seconds. Stop n Glo buffer (Promega, Madison, Wl) was 
added to stop the firefly luciferase activity and to provide substrate for the renilla 
luciferase activity. The activity of renilla luciferase was measured on the 
luminometer using the same parameters as firefly luciferase on luminometer. In 
rat cells, the values for firefly luciferase activity for each sample were normalized 
to the values for renilla luciferase for the same sample. In human cells, the 
values for renilla luciferase were not detected above the baseline and hence a 
different method of normalization was necessary. For human cells, protein 
concentration of each sample was determined by BCA protein assay kit (Pierce, 
Rockford, IL). Luciferase activity was normalized for the protein concentration of 
each sample to get the activity in counts/mg protein for each sample. For each 
treatment, cells were transfected at least in duplicates.
Development of chronic glomerulonephritis in experimental animals
The following protocol was approved by the institutional animal care and 
use committee of Eastern Virginia Medical School under the title “Prevention of 
glomerulosclerosis by rho-kinase inhibition" (Approval # 02-010).
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Production of injury
Repeated Injections of anti-thymocyte serum (ATS) were used to induce 
chromic glomerulonephritis in experimental rats. In three experimental groups, 
six male Sprague-Dawley rats were injected with 25 mg/kg sheep anti-thymocyte 
serum (30 mg/ml) through tail vein injections. Four weekly injections of ATS were 
given to the animals. The ATS injections were immediately followed by injection 
of 1.2 ml normal sheep serum as a source of complement. The doses of ATS 
were adjusted each week according for the weight gain. A control group (Group 
1) of six animals was injected with equal volumes of normal saline.
Treatment
Out of the three groups that received ATS-complement, one group did not 
receive any treatment and hence served as the injury group (Group 2). The 
remaining two of the three ATS-complement groups received 30 mg/kg/day HA- 
1077 in drinking water. The concentration of the drug in the drinking water was 
determined according to the average weight of the animal and average daily 
water consumption. Within the two treatment groups, one group (Group 3) was 
treated from one day before the first injection to see if the treatment prevents the 
onset of the injury, whereas the other group (Group 4) was treated one week 
after the injury to see if the progression of the disease was altered. The animals 
were fed normal rat diet and were allowed to drink ad lib. After four weekly 
injections, animals were treated and observed for 6 more weeks (total of 4+6=10 
weeks) to allow progression of the chronic disease. At the end of the tenth week, 
animals were killed and samples were collected for analyses.
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Study groups
1: Normal saline injection alone 
2: ATS-complement injection
3: ATS-complement+ HA-1077 treatment started 1 day before the first injection 
4: ATS-complement+HA-1077 treatment started 1 week after the first injection 
Sample collection 
Urine
After 24-hour acclimatization in metabolic collection chambers, urine 
samples representing next 24-hour urine collection were collected one day 
before the first injection and at the end of 2, 4, 6, 8, 10 weeks. The first two 
collections showed contamination by food particles and hence, the food was 
removed from the chambers for the later set of collections.
Blood pressures
The tail-cuff method was used to measure blood pressure at the end of 
the study.
Serum
At the end of the study animals were anesthetized with intraperitoneal 
injection of sodium pentobarbital (Nembutal). Blood was collected from 
abdominal aorta for serum preparation.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
51
Tissue samples
Kidneys were harvested in ice-cold Hanks’s balanced salt solution. 
Animals were killed by removal of the heart. One kidney from each animal was 
pooled with others from the same group for isolation of glomeruli through 
differential sieving method. Most of the glomeruli (90%) were suspended in Trizol 
for isolation of RNA and the remaining glomeruli were suspended in 
electrophoresis sample buffer for SDS-PAGE and Western Blot analysis. The 
second kidney was bisected and one half was cut into thin slices, some of which 
were fixed in paraformaldehyde (4% in PBS) overnight, and then snap frozen for 
immunohistochemistry. The remaining slices were fixed in 10% buffered formalin 
for paraffin section preparation. The other half was cut into multiple thin slices 
and snap frozen in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) 
for immunohistochemistry or laser capture microdissection (LCM).
Histology and Immunohistochemistry
The sections from formalin-fixed tissue were stained with mason trichrome 
staining to visualize ECM deposition. The sections from snap frozen tissue were 
stained with a-SMA antibody as described in immunocytochemistry section.
Statistical Analysis
The statistical significance of the results was determined using Student’s 
paired t-test. A p-value of <0.05 was considered statistically significant. 
Experimental variation is reported as standard error of the mean in the bar 
graphs (except where indicated differently).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
CHAPTER 3
PROFILING THE EFFECTS OF ACTIN CYTOSKELETON ON EXPRESSION 
OF MULTIPLE GENES 
Introduction
As described in chapter 1, studies in this lab showed that changes 
in actin polymerization regulate a-SMA expression and hypertrophy in cultured 
mesangial cells suggesting that the actin cytoskeleton may regulate 
myofibroblast differentiation [28]. The role of the cytoskeleton as an important 
regulator of gene expression has also been supported by many other studies. 
Studies by Folkman and Moscona on cell-spreading [33], and Ingber on 
mechanical transduction and cell functions [34, 113, 114] provided early 
evidence for the role of actin cytoskeleton in the gene regulation. More recently 
specialized actin cytoskeleton locations have been identified for integration of 
signaling such as JNK signaling [39-42], The importance of localization of mRNA 
in effective protein translation has also become evident [43], The collective 
evidence suggests that the actin cytoskeleton is a highly specialized network of 
fibers that precisely regulate multiple cellular responses. But the precise 
regulatory pathways and mechanisms have not been characterized. Also the list 
of genes that are affected by actin polymerization is far from complete.
The regulatory effect of actin cytoskeleton on a-SMA expression in 
myofibroblast differentiation and the evidence from the literature suggested that
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other genes could also be regulated in a similar manner. Also, the inhibition of 
hypertrophy suggested that multiple genes could be simultaneously regulated by 
the actin cytoskeleton. It was therefore hypothesized that other genes associated 
with the myofibroblast phenotype are also regulated by changes in actin 
polymerization. The aim of the next experiment was to identify the effect of the 
actin cytoskeleton on a panel of genes related to myofibroblast differentiation. 
Experimental model
Recently, DNA arrays consisting of multiple genes spotted on a glass 
coverslip or a nylon membrane have become available to facilitate rapid and high 
throughput analysis of large populations of genes. Commercially available arrays 
contain functionally related genes on the same array allowing a highly relevant, 
focused, and time- and cost-effective analysis of gene expression.
Since myofibroblasts are largely responsible for extracellular matrix 
production in fibrotic diseases, one such array (cell interaction array) containing 
genes related to cell-interaction and extracellular matrix was used to study the 
role of actin cytoskeleton in myofibroblast differentiation. The Cell Interaction 
array (Clontech, Palo Alto, CA) contains a total of 265 cDNAs immobilized on a 
nylon membrane. The genes on this Cell-lnteraction array include extracellular 
matrix proteins; cell-cell adhesion receptors; matrix adhesion receptors; growth 
factors, chemokines, cytokines and their receptors; neuropeptides; cell surface 
antigens; extracellular transporters and carrier proteins; metalloproteinases; 
serine proteases; protease inhibitors, oncogenes and tumor suppressor genes; 
intracellular transducers, effectors and modulators; G proteins; cell-cycle related
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proteins and house-keeping genes covering a broad range of relevant gene 
population. A detailed list of these genes can be found on the internet at 
http://www.clontech.com/clontech/atlas/genelists/7746-1_HuCelllnt.pdf. The gene 
expression profile of cells with depolymerized actin cytoskeleton (CytB treated 
cells) was compared with that of cells containing intact actin cytoskeleton 
(untreated serum-starved cells) as described in Chapter 2.
Results
Actin depolvmerization affects expression of multiple genes
Between control and CytB-treated cells a total of 74 genes were detected 
on a 265-gene cell-interaction array, out of which 65 genes were detected in both 
the conditions and 9 genes were detected under only control conditions (Fig. 6). 
Using an arbitrarily defined criteria of either more than a 2-fold increase or more 
than 50% inhibition as a significant change, 10 genes were decreased and 4 
genes were increased upon CytB treatment. All 9 genes expressed only under 
control conditions were excluded from the final analysis since their expression 
was very close to the base-line. Table 3 shows the ratio of signal intensities in 
CytB treated cells and untreated control cells in serum-free media. The genes 
that decreased after CytB treatment, mainly represented extracellular matrix 
components or other molecules that favor increased matrix deposition. In 
contrast, 3 of the 4 genes that increased after CytB treatment, decrease matrix 
deposition either by direct fibrolysis (tPA, MMP11) or by inhibiting pro-fibrotic 
growth factors (decorin). These changes suggest that the overall effect of actin
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Fig. 6. DNA array analysis of effect of actin depolymerization on gene 
expression. Serum-starved human mesangial cells were treated with 1.0 pM 
CytB for 24 hours in serum-free media. 32P-labeled gene-specific probes 
prepared from cellular poly A mRNA were hybridized with the membrane 
overnight. After washing, membranes were exposed to phosphorimager plates 
for 3 days. Scanned blots were analyzed by Atlaslmage software for differences 
in gene expression (n=1). The top blot represents gene expression profile of cells 
in serum-free media, whereas the bottom panel represents gene expression 
profile of cells treated with 1.0 pM CytB. The panel on left shows house-keeping 
genes and negative control spots. The spots corresponding to PAI-1 (oval) and 
tPA (rectangle) genes are highlighted for comparison on both the blots.
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Table 3. Summary of changes in gene expression on DNA array analysis
Gene CytB:S- ratio
A. Genes showing decreased expression after Cytochalasin B treatment
Endothelial plasminogen activator inhibitor-1 precursor (PAI-1) 0.093
Insulin-like growth factor binding protein 5 precursor (IGFBP5) 0.210
Fibronectin receptor alpha subunit (FNRA) 0.310
Insulin-like growth factor binding protein 3 precursor (IGFBP3) 0.314
Tumor metastatic process associated protein (NM23) 0.326
Fibronectin precursor (FN) 0.339
Hypoxanthine-guanine phophoribosyltransferase (HPRT) 0.370
Collagen 3 alpha 1 subunit precursor (COL3A1) 0.382
Collagen 1 alpha 2 subunit precursor (COL1A2) 0.393
Collagen 4 alpha 2 subunit precursor (COL4A2) 0.397
B. Genes showing increased expression after Cytochalasin B treatment
Tissue-type plasminogen activator precursor (tPA) 2.840
Bone proteoglycan II precursor (PGS2), decorin (DCN) 3.250
Junction plakoglobin (JUP); desmoplakin 3 (DP3) 3.875
Matrix metalloproteinase 11 (MMP11), stromelysin 3 9.000
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depolymerization favors increased matrix degradation and decreased matrix 
accumulation. The net effect may be a decrease in extracellular matrix. 
Confirmation of DNA array results using Northern and Western Blotting
The results obtained by the initial screening experiments required both 
confirmation and more accurate quantification of the changes using conventional 
methods such as Northern blot analysis. The changes in protein expression were 
also examined to confirm similar effects on mRNA and protein expression. Out of 
14 genes identified by the array experiment, PAI-1 and tPA, the members of 
plasminogen activator system, are particularly relevant to the overall objective of 
understanding mechanisms of myofibroblast-like differentiation and regulation of 
ECM accumulation. PAI-1 is a natural inhibitor of the plasminogen activation by 
tPA. CytB not only decreases PAI-1 expression, but also increases tPA 
expression. These changes may result in increased and unopposed actions of 
tPA leading to more activation of plasminogen into plasmin. Activated plasmin in 
turn degrades ECM. Consequently, the balance between tPA and PAI-1 
determines the rate of ECM turnover. A relative increase in tPA leads to 
increased degradation of ECM. In contrast, a relative increase in PAI-1 leads to 
inhibition of ECM degradation and increased ECM deposition as seen in renal 
fibrosis. Such an increase in PAI-1 expression and resulting ECM deposition are 
associated with myofibroblast-like activation of mesangial cells. Thus, changes in 
tPA and PAI-1 expression on gene array are directly pertinent to myofibroblast 
differentiation and fibrosis.
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Therefore, the changes in PAI-1 and tPA expression seen on DNA array 
were confirmed first using conventional methods such as Northern blot and 
Western blot analyses. mRNAs from cells treated with actin depolymerizing 
agents CytB (direct inhibitor of actin polymerization) and Y-27632 (inhibitor of 
signal-mediated actin polymerization) were analyzed. The Northern blot analysis 
showed two PAI-1 transcripts at 2.8 kb and 3.2 kb positions resulting from two 
polyadenylation sites in the PAI-1 gene [115]. The results showed that in 
presence of serum (S+ conditions), inhibition of actin polymerization with CytB 
decreased PAI-1 mRNA expression in a time and dose dependent manner (Fig. 
7). The effect of CytB was apparent at 24 hours and continued at 48 and 72 
hours (Fig. 7A). The dose response shows that the minimum dose of CytB 
required to produce a visible effect on PAI-1 mRNA was 0.4 pM at 24 hours.
CytB caused >50% inhibition of PAI-1 mRNA expression at 1 pM concentration 
(Fig. 7B). We used 1 pM (0.5 pg/ml) CytB for the rest of the study. In serum- 
starved cells, inhibition of Rho-signaling by 10 pM Y-27632 also inhibited PAI-1 
mRNA expression in a time-dependent manner (Fig. 7C). The effect was evident 
as early as 4 hours and continued at 8, 24 and 48 hours. Similar inhibitory effects 
of actin depolymerization on PAI-1 protein expression were confirmed in the 
laboratory by other investigators. An increase in tPA expression by actin 
depolymerization as shown in the array experiment was also confirmed at mRNA 
and protein levels by Northern blot and Western blot analyses respectively in the 
lab.
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Fig. 7. Effect of actin depolymerization on PAI-1 mRNA expression in 
human mesangial cells. (A) Time-course of effect of 1.0 pM CytB (8, 24, 48 and 
72 hours) on PAI-1 mRNA expression in serum-fed cells by Northern blot 
analysis (n=1). CytB treatment blocks PAI-1 expression at 24, 48 and 72 hours, 
(B) Dose-response analysis of effect of CytB (0.1, 0.2, 0.4, 1 and 2 pM) on PAI-1 
mRNA expression in serum-fed cells by Northern blot analysis (n=1). CytB 
concentrations of 0.4, 1 and 2 pM block PAI-1 mRNA expression. (C) Time- 
course of effect of 10 pM Y-27632 (8, 24, 48 and 72 hours) on PAI-1 mRNA 
expression in serum-starved cells by Northern blot analysis (n=1). Y-27632, an 
inhibitor of Rho-kinase that blocks Rho-mediated actin polymerization, blocks 
PAI-1 mRNA expression at 24, 48 and 72 hours.
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In summary, the DNA array analysis showed that actin depolymerization 
coordinately regulated cell-interaction and ECM-related genes in human 
mesangial cells. The inhibition of PAI-1 and increase in tPA expression were 
confirmed by Northern blot and Western blot analyses. To further investigate the 
mechanisms of actin cytoskeleton mediated regulation of PAI-1 and tPA 
expression in pathophysiological context, TGF|3 treatment was used as a model 
system as described in the next chapter.
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CHAPTER 4 
EFFECT OF TGFp ON PAI-1 EXPRESSION 
Introduction
Results of the array experiment and subsequent confirmation with Northern 
and Western blot analysis showed that actin depolymerization changed PAI-1 
and tPA in opposite directions. PAI-1 was studied first and in more detail than 
tPA because PAI-1 expression has been correlated with myofibroblast 
differentiation [19, 25], Moreover, PAI-1 acts as the gatekeeper of the fibrolytic 
cascade regulating the activity of plasminogen activators including tPA. 
Therefore, functionally changes in PAI-1 expression are more directly related to 
tissue fibrosis.
Since transforming growth factor (3 (TGFP) is the major regulator of PAI-1 
expression in disease, the ability of actin depolymerization to antagonize its 
effect on PAI-1 expression was examined. Also, TGFp was chosen for further 
studies particularly since it plays a central role in regulating myofibroblast 
differentiation and tissue fibrogenesis [116-120]. In the kidney, expression of 
TGFp by mesangial cells increases extracellular matrix (ECM) production and 
inhibits matrix degradation [88, 89, 91, 121]. The net result is an increase in 
ECM deposition and glomerulosclerosis [90, 122]. Consequently, inhibition of 
TGFp signaling was shown to protect against renal fibrosis [88, 123]. It was 
therefore important to understand the pathways and mechanisms involved in
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TGFP-induced fibrosis. Experimentally, serum-free culture conditions were 
selected to allow the study of TGFp without other serum-factors.
The overall experimental approach was to induce PAI-1 expression by TGFp 
and to determine the effects of changes in actin polymerization on PAI-1 
expression in basal as well as TGFp-induced states. Since the effects of growth 
factors can vary according to cell-type and cell-culture conditions; the effective 
dose, effective time period and the magnitude of effect of TGFP on PAI-1 
expression in human mesangial cells were determined first.
Experimental model
Primary cultures of human mesangial cells between passages 5 and 9 (P5- 
P9) were used in the study. Initially, the cells were cultured in RPMI media 
containing 16.7% fetal bovine serum (FBS). Cells were serum-starved at 60-80% 
confluence. After 24 hours of serum starvation, TGFp was added to the cells.
The effects on PAI-1 expression were examined at the indicated time-points. 
Serum-free media, being free of other growth factors, allows the study of effects 
of TGFp alone. Also, serum starvation increases the stress fiber content of the 
cells which is consistent with myofibroblast-like phenotype [26]. The effects of 
inhibition of actin polymerization can be easily compared to untreated control 
cells that have abundant stress fibers. A culture in serum-free media helps in 
studying the regulation of basal expression of PAI-1, where as treatment with 
TGFp allows the study of induced PAI-1 expression.
To determine the optimum dose of TGFp and the optimum duration of 
treatment, human mesangial cells were treated with increasing doses of TGFp
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for 0, 1, 2, 4, 8, 24 and 48 hours. At each time point, supernatants (conditioned 
media) were stored for detection of PAI-1 protein and the cells were lysed in 
TRIzol for RNA isolation. PAI-1 protein was detected from conditioned media 
using Western blot analysis with enhanced chemiluminescence detection, 
whereas PAI-1 mRNA was detected using quantitative real-time RT-PCR.
Results
Quantification of PAI-1 mRNA using real-time PCR analysis
PAI-1 mRNA from cultured human mesangial cells was successfully 
detected by a reverse transcription reaction in a thermal cycler (MJ Research, 
Reno, NV) followed by a quantitative real-time PCR analysis on Roche 
Lightcycler (Roche Diagnostics, Indianapolis, IN). The Lightcycler instrument 
measures fluorescence emitted by SYBR Green I, a double-stranded DNA 
binding dye, at the end of each cycle during the log-linear phase of the PCR and 
generates an amplification curve by plotting changes in fluorescence intensities 
against cycle number (Fig. 8A, Fig. 9A). The cycle at which the fluorescence 
signal rises above the background signal is called the crossing point, which is 
directly proportional to the concentration of the target DNA. The crossing point for 
an unknown sample can be compared to crossing points of known standards for 
quantification of sample concentration. The values for PAI-1 concentration were 
derived in picograms, which were further normalized to similarly obtained values 
for a reference gene, ubiquitin (UBC), in each sample. Ubiquitin was selected as 
the reference or house-keeping gene because it is expressed constitutively in the 
cells and its level did not change upon the experimental treatments (refer to table
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Slope = -3.77
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Fig. 8. PAI-1 standard curve for quantitative real-time PCR analysis. (A)
Amplification of PAI-1 plotted as fluorescence vs. cycle number. Each sample is 
represented in a uniquely colored line on the real-time PCR software, allowing 
tracing of amplification of individual samples. (B) PAI-1 standard curve plotted as 
cycle number vs. log concentration showing a linear standard curve (r= -1). (C) 
Real-time monitoring of melting curve analysis of PCR products plotted as 
fluorescence vs. cycle number showing only one PCR product corresponding to 
PAI-1. (D) Melting curve analysis data plotted as changes in fluorescence signal 
overtime (dF/dT) vs. temperature. Presence of only one melting peak in this 
reaction corresponding to melting temperatures of PAI-1 (-85.5 C) indicates 
specificity of the amplification reaction and absence of primer-dimers.
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4). Also it is expressed at relatively lower levels, which is a desired property for 
real-time PCR analysis allowing detection of smaller changes in the expression 
unlike genes that are too abundant in the cells such as 18S.
Standard curves for PAI-1 and UBC were developed by performing real­
time PCR on known concentrations of purified cDNA (Fig. 8, Fig. 9). For every 
experiment, one purified standard cDNA (0.01 pg for PAI-1 and 100 pg for UBC) 
with similar crossing point as a representative experimental sample was also run 
with the samples. The sample concentrations were calculated by the software in 
a two-step process. First, the software compared the crossing point of the known 
standard in each experiment with the previously saved standard curve to account 
for the PCR efficiency. Next, the concentrations of the unknown samples were 
derived by comparing the sample crossing point to the standard crossing point.
Following completion of the PCR, a melting curve analysis of PCR 
products was performed by the instrument to confirm the purity of the reaction. 
Melting curve analysis measures changes in fluorescence intensities as the 
temperature is gradually increased. Separation of double stranded DNA with 
increasing temperature caused an initial gradual fall in the fluorescence signal 
followed by a precipitous fall (Fig. 8C, Fig. 9C). When these changes in 
fluorescence intensity with time were plotted against the temperature, a melting 
peak corresponding to the maximum changes in signal intensity (dF/dT) at 
melting temperature (Tm) was seen (Fig. 8D, Fig. 9D). The number of melting 
peaks in each reaction indicates the number of target sequences being amplified. 
A unique peak at the melting temperature of the target sequence indicated
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Fig. 9. UBC standard curve for quantitative real-time PCR analysis. (A)
Amplification of UBC plotted as fluorescence vs. cycle number. Each sample is 
represented in a uniquely colored line on the real-time PCR software, allowing 
tracing of amplification of individual samples. (B) UBC standard curve plotted as 
cycle number vs. log concentration showing a linear standard curve (r= -1). (C) 
Real-time monitoring of melting curve analysis of PCR products plotted as 
fluorescence vs. cycle number showing only one PCR product corresponding to 
UBC. (D) Melting curve analysis data plotted as changes in fluorescence signal 
over time (dF/dT) vs. temperature. Presence of only one melting peak in this 
reaction corresponding to melting temperatures of UBC (~82°C) indicates 
specificity of the amplification reaction and absence of primer-dimers.
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absence of non-specific amplification and primer-dimers in the reaction. As an 
added quality control measure to ensure the size of the product and to rule out 
non-specific amplification, the PCR products from standard curve samples and 
representative experimental samples were run on 8% agarose gel (Fig. 10, Fig.
11D). Gel electrophoresis was used as a quality control tool only to visualize the 
number and size of products in each reaction. It was not used for quantification of 
mRNA.
Figures 8 and 9 show standard curves for real-time PCR analysis of PAI-1 
and UBC respectively. Figure 10 shows gel electrophoresis of PCR products 
from PAI-1 and UBC PCR standard curves.
TGFB dose-response on PAI-1 mRNA expression
The effect of TGFp on PAI-1 mRNA were studied using real-time 
quantitative PCR analysis with lightcycler PCR instrument. Figure 11 shows a 
representative real-time monitoring of PAI-1 and UBC amplification at the end of 
each cycle in panel A. Panels B and C represent melting curve analysis of PAI-1 
and UBC at the end of PCR cycling showing a single peak each for both the 
genes. Panel D show gel electrophoresis of PCR products showing a single 
product for each gene correlating with the expected band size.
To determine the effective dose of TGFp, human mesangial cells were 
serum-starved at 60-80% confluence. After a 24-hour serum-starvation, 1, 2, 5, 
7.5 or 10 ng/ml TGFp was added to serum-free media for 8 hours. Total cellular 
RNA was isolated using TRIzol method. The changes in PAI-1 mRNA expression 
were detected using quantitative real-time RT-PCR analysis. In two separate
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Fig. 10. Gel-electrophoresis of standard curve PCR products. Aliquots of 
PCR products (2 pi out of 20 pi total) were run on 8% acrylamide gel followed by 
ethidium bromide staining. (A) PAI-1 and (B) UBC PCR products show a single 
band at expected base-pair location confirming specific amplification of 
respective templates.
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Fig. 11. Representative images from quantitative real-time PCR of PAI-1 and 
UBC from experimental samples. (A) Amplification of PAI-1 and UBC plotted 
as fluorescence vs. cycle number. Each line is represented in different color on 
the real-time PCR software, allowing tracing of amplification of individual 
samples. The crossing points for both PAI-1 and UBC fall within the bars marking 
approximately cycles 15 and 22. (B) Real-time monitoring of melting curve 
analysis of PCR products plotted as fluorescence vs. cycle number showing two 
PCR products corresponding to PAI-1 and UBC. (C) Melting curve analysis data 
plotted as changes in fluorescence signal over time (dF/dT) vs. temperature. 
Presence of only two melting peaks in this reaction corresponding to melting 
temperatures of UBC (~82°C) and PAI-1 (~85.5°C) indicate specificity of the 
amplification reaction and absence of primer-dimers. (D) Gel electrophoresis of 
PCR products from representative experimental samples show a single PCR 
product of expected base-pair size in each reaction.
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experiments, treatment with 1, 2, 5, 7.5 and 10 ng/ml TGFp increased average 
PAI-1 mRNA expression to 381.9%, 323.1%, 443.3%, 485.1% and 287.9% of 
untreated control respectively (Fig. 12A).
TGFB dose-response on PAI-1 protein expression
To determine the effective dose of TGFp on PAI-1 protein expression, 
human mesangial cells were serum-starved at 60-80% confluence in 2-wells per 
condition in 6-well plates. After 24-hour serum-starvation, 1, 2, 5, 7.5 or 10 ng/ml 
TGFP was added to serum-free media for 24 hours. Conditioned media was 
analyzed for changes in PAI-1 protein using Western blot analysis. In a single 
experiment, treatment with 1, 2, 5, 7.5 and 10 ng/ml TGFp changed average PAI- 
1 protein expression to 125.9%, 100.9%, 79.3%, 133.6% and 283.6% of 
untreated control respectively (Fig. 12B). The maximum increase in PAI-1 protein 
was seen with 10 ng/ml TGFp. Although TGFp showed an effect at lower 
concentrations, it was inconsistent. Fan et al. previously showed that renal 
tubular epithelial-myofibroblast transdifferentiation in vitro required TGFp at 
concentrations between 10 to 50 ng/ml [119]. Others have also shown 10 ng/ml 
TGFp as an effective dose [124, 125], The effectiveness of higher concentration 
of TGFp correlates with high serum TGFp levels seen in patients with chronic 
and end-stage renal disease [126].
Since 10 ng/ml TGFp showed consistent effects on both mRNA and 
protein expression, that dose was used in the remaining experiments.
Previously, Motojima et al. also reported 10 ng/ml TGFp to be the most effective 
dose for the induction of PAI-1 in rat mesangial cells [82],
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TGFB time-course of PAI-1 mRNA and protein expression
To determine the optimum length of time of TGF|3-treatment for maximum 
PAI-1 mRNA and protein expression, human mesangial cells were serum-starved 
at 60-80% confluence and after 24-hours of serum starvation, 10 ng/ml TGF(3 
was added to serum-free media for 1,2,4, 8, 24 and 48 hours. At each time 
point, conditioned media were saved for protein analysis and cells were used for 
RNA analysis. In three separate experiments, treatment with 10 ng/ml TGFp for 
1, 2, 4, 8, 24 and 48 hours changed PAI-1 mRNA expression to 180.4±22.8%, 
186.0±30.7%, 191.0±23.5%, 100.1 ±13.5% and 90.6±8.7% of respective time- 
matched controls (Fig. 13A). At the same time, the basal expression of PAI-1 
mRNA at 2 and 4 hours decreased to 90.9±10.9% and 59.7±9.4% (p<0.05) of 0- 
time point control. At 8, 24 and 48 hours, basal PAI-1 mRNA expression changed 
to 105.0± 7.5%, 134.7±14.7% and 146.2% of 0-time point control.
In the same set of experiments, the effect on PAI-1 protein expression was 
examined using Western blot analysis at 8, 24 and 48 hours in conditioned 
media. PAI-1 expression could not be detected at 8 hours. At 24 hours TGFp 
increased PAI-1 protein to 424 ± 104.6% of time-matched control (Figre 13B). At 
48 hours, the increase in PAI-1 protein was 181.9% and 131.7% in two separate 
experiments (average 158%). Thus, 10 ng/ml TGFp increased PAI-1 mRNA
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Fig. 12. Dose-reponse analysis of TGFp induction of PAI-1 expression.
Serum-starved human mesangial cells were treated with 0, 1, 2, 5, 7.5 and 10 
ng/ml TGFp for 8 (mRNA) or 48 (protein) hours (A) PAI-1 mRNA expression 
measured by quantitative real-time PCR analysis shows an increase with TGFp 
treatment. Each bar represents the average increase at corresponding 
concentration normalized to untreated control (n=2). The ends of error bars show 
value for each experiment. (B) PAI-1 protein expression was measured in 
conditioned media using Western blot analysis with chemiluminiscence detection. 
Treatment with 10 ng/ml TGFp increased PAI-1 protein expression to 283.6% of 
untreated control (n=1).
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expression maximally and consistently at 8 hours, whereas it increased PAI-1 
protein expression maximally at 24 hours. The maximum increase in PAI-1 
protein expression at 24 hours is consistent with previous studies by Matsumoto 
et al [127].
In summary, the results of time-course and dose-response analysis of 
TGFP on PAI-1 expression showed 10 ng/ml TGFp as the effective dose and, 8- 
hour and 24-hour as effective treatment duration for mRNA and protein studies 
respectively. The remaining studies were performed using these time points.
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Fig. 13. Time-course analysis of TGFp induction of PAI-1 expression.
Serum-starved mesangial cells were treated with or without 10 ng/ml TGFp for 
indicated lengths of time. (A) Changes in PAI-1 mRNA were detected using 
quantitative real-time PCR analysis (n=3 except 48 hours: n=2). (B) Changes in 
PAI-1 protein expression were measured in conditioned media using Western 
blot analysis with chemiluminescence detection at 24 (n=3) and 48 (n=2) hours. 
The vertical bars and the error bars represent the mean PAI-1 values and SEM 
respectively. The value of either 0-hour (A) or time-matched (B) untreated control 
is set at 100%. *:p<0.05 compared to time-matched control, f :  p<0.05 compared 
to 0-hr time-point.
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CHAPTER 5
EFFECT OF CHANGES IN ACTIN POLYMERIZATION ON TGFp-INDUCED 
PAI-1 EXPRESSION 
Introduction
The results of earlier chapter confirmed induction of PAI-1 by TGFp in 
human mesangial cells. The role of actin cytoskeleton in this induction was 
examined next. Previous studies in this lab showed that changes in actin 
cytoskeleton regulate a-SMA gene expression, a marker of myofibroblast 
differentiation, and hypertrophy in mesangial cells [28]. Like a-SMA expression, 
de novo expression of PAI-1 is also seen with myofibroblast differentiation. It is 
possible that the expression of PAI-1 is also regulated in a cytoskeleton- 
dependent manner similar to that of a-SMA.
The Rho family of small GTPases controls organization of the actin 
cytoskeleton [27], Rho activates Rho-kinase, a serine-threonine kinase that acts 
through downstream kinases to stabilize actin polymers e.g. stress fibers and 
adhesion. The small GTPases, Rho and Rac are both involved in the regulation 
of PAI-1 expression. Inhibition of Rho by the C3 exoenzyme decreased PAI-1 
production in rat proximal tubules [105] and aortic endothelial cells [106]. In 
chicken atrial cells, co-transfection with dominant-negative RhoA decreased PAI- 
1 promoter activity, whereas dominant-active RhoA increased promoter activity 
[107], In smooth muscle cells, Y-27632, a Rho-kinase inhibitor, attenuated 
expression of PAI-1 in response to Angiotensin II (Angll) [81]. These suggest a
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role of Rho GTPases as intracellular mediators of diverse stimuli leading to PAI-1 
expression. Rho has also been shown to regulate TGFp-mediated gene 
expression. In human mesangial cells, inhibition of Rho and its downstream 
effector Rho-kinase blocked TGFp-mediated expression of a1 collagen, a 
component of ECM [87]. It is possible that Rho may play a similar role in 
regulating TGFp-mediated expression of PAI-1.
Since regulation of actin polymerization is a major function of the Rho 
family, the working hypothesis that Rho-mediated changes in actin 
polymerization modulate TGFp-induced PAI-1 expression was examined. If Rho- 
signaling worked through actin cytoskeleton for regulation of PAI-1 expression, 
inhibition of actin cytoskeleton would produce similar results as the inhibition of 
Rho.
Experimental model
Pharmacologic agents that stabilize or destabilize the polymeric actin 
cytoskeleton by acting at different levels (Fig. 4) were used to test the hypothesis 
that Rho GTPase regulates TGFp-induced PAI-1 expression through changes in 
actin polymerization. The treatment conditions included (a) inhibition of signal- 
mediated actin polymerization by inhibiting Rho GTPase (Clostridium difficile 
Toxin B, 10 pM) or its downstream effector Rho-kinase (HA-1077 (20 pM), Y- 
27632 (10 pM)) [87, 128, 129]; (b) inhibition of actin polymerization by agents 
directly binding to actin polymers (Cytochalasin B, 1 mM) or monomers 
(Latrunculin B, 0.1 pM) [130, 131]; and (c) increase in polymeric actin content by
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stabilizing the actin polymers (Jasplakinolide, 50 nM) [132], The final outcome 
was either an increase or a decrease in the actin polymers in the cells.
Results
Actin depolvmerization inhibits TGFB-induced PAI-1 mRNA expression
First, the effect of actin depolymerizing agents on TGFp-induced PAI-1 
mRNA expression was examined (Fig. 14). Either Toxin B (Fig. 14A), a direct 
inhibitor of Rho, or Y-27632 (Fig. 14B) and HA-1077 (Fig. 14B), both inhibitors of 
a downstream effector of Rho, Rho kinase (ROCK), were used to inhibit Rho- 
mediated actin polymerization. ToxinB, Y-27632 and HA-1077 decreased basal 
PAI-1 mRNA expression to 19.5±5.6%, 52.8±5.4%, 59.3±17.9% of untreated 
control respectively, and decreased TGFp-induced PAI-1 expression to 
30.1±7.6%, 51.1 ±6% and 55.8±15.6% of TGFp-treated control respectively (Fig. 
14A-C). Direct inhibition of the actin polymerization by CytB and LatB decreased 
basal PAI-1 expression to 29.9 ±3.3% and 45.3±16% of untreated control 
respectively, and decreased TGFp-induced PAI-1 expression to 35.2±6.5% and 
49.7±16.5 of TGFp-treated control respectively (Fig. 14D, E). Northern blot 
analysis (Fig. 14G) confirmed these results. This observation, that the effects of 
Rho-inhibition are mimicked by direct actin depolymerization, suggests that the 
effects of Rho on PAI-1 expression are mediated by the changes in actin 
cytoskeleton.
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Fig. 14. Effect of actin polymerization on TGFp-induced PAI-1 mRNA 
expression. Serum-starved mesangial cells were treated with (A) 10 pM Toxin 
B, (B) 10 pM Y-27632, (C) 20 pM HA-1077, (D) 1 mM CytB, (E) 0.1 pM LatB or 
(F) 50 nM JAS for 1-hour prior to 8-hour treatment with 10 ng/ml TGFp (n=3). 
The changes in PAI-1 mRNA were measured using real-time PCR analysis (A-F) 
and Northern blot analysis (G). The vertical bar and the error bars represent the 
mean PAI-1 mRNA values and SEM for the experimental condition. The value for 
untreated control is set at 100%. The value for untreated control is set at 100%. 
*:p<0.05, **:p<0.01 and ***:p<0.005 compared to S- control, t :  P<0.05 and t t t :  
p<0.005 compared to TGFP treated control. (G) Representative Northern blot 
showing inhibition of basal and TGFp-induced PAI-1 expression with actin 
depolymerization (n=2).
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Actin depolvmerization inhibits TGFB-induced PAI-1 protein expression
To ensure that the changes in PAI-1 mRNA expression were reflected at 
the level of protein expression, the effect of the actin-depolymerization on PAI-1 
protein expression was examined using Western blotting.
The effect on cellular PAI-1 protein was examined first (Fig. 15A). Cell- 
lysates scraped in 1x sample buffer were used to detect changes in PAI-1 
protein. Serum-starved mesangial cells were pre-treated with CytB for one hour 
before 24 or 48 hour treatments with TGFp. TGFp had no apparent effect on 
PAI-1 expression at 24 or 48 hours. This is possibly due to saturation of PAI-1 
binding sites (vitronectin) on the substratum during prior culture [133], CytB 
blocked PAI-1 expression in both basal and TGFp-treated conditions. At 24 
hours, CytB blocked basal and TGFp-treated PAI-1 expression to 14.4% and 
38.8% of their respective controls. At 48 hours, CytB blocked basal and TGFP- 
treated PAI-1 expression to 4.2% and 46.1% of their respective controls.
Active PAI-1 is rapidly secreted from the cells upon synthesis [25]. 
Therefore, the conditioned media was examined for changes in PAI-1 protein 
expression in response to TGFp. In the same experiment, changes in PAI-1 
levels were clearly apparent in conditioned media (Fig. 15B). At 24 hours, TGFp 
increased PAI-1 expression to 273% of control. CytB blocked basal and TGFp- 
induced PAI-1 expression to 7.9% and 20.7% of their respective controls. At 48 
hours, TGFp increased PAI-1 expression to 217% of control. CytB blocked basal 
and TGFp-induced PAI-1 expression to undetectable levels.
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Fig. 15. Effect of TGFp and actin depolymerization on PAI-1 protein 
expression. Serum starved mesangial cells were pre-treated with 1 mM CytB 
prior to 24-hour treatment with 10 ng/ml TGFp. Cell-lysates (A) and Conditioned 
media (B) were analyzed for PAI-1 detection using Western blot analysis (n=1). 
An increase in PAI-1 upon TGFp treatment is seen in conditioned media (B) but 
not in cell lysates (A). CytB blocks PAI-1 expression, under basal and TGFp- 
treated conditions, in both cell lysates and conditioned media.
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Next, the effect of a panel of actin cytoskeleton inhibitors on TGFp- 
induced PAI-1 expression was examined using conditioned media (Fig. 16). The 
changes in PAI-1 protein expression were consistent with the changes seen in 
mRNA. Densitometric analysis of the Western blots showed that TGFp maximally 
stimulates PAI-1 expression to 304.3±31.4% of control at 24 hours. Toxin B, Y- 
27632, FIA-1077, CytB and LatB inhibited basal PAI-1 expression to 31.7±4.4%, 
42.2±7.8%, 31±3.7%, 37.3±5.6% and 44.4±7.8% of control respectively, and 
inhibited TGFP-induced PAI-1 expression to 26.8±7%, 38.6±4.9%, 33.6±6.9%,
21.1 ±4.1 % and 31±8.3% of TGFp-treated control respectively. A representative 
Western blot is shown in Fig. 16A. These results suggest that agents with actin 
depolymerizing activity blocks TGFp-induced PAI-1 expression regardless of 
their mechanism of action.
Immunocvtochemical analysis of effect of actin depolvmerization on 
TGFB-induced PAI-1 expression
In culture, secreted PAI-1 binds to vitronectin on the pericellular 
substratum and shows characteristic intracellular and extracellular distribution 
[134], Indirect immunofluorescence microscopy was used to visualize the effects 
of Y-27632 and CytB on PAI-1 deposition on the substratum (Fig. 17). These 
cells were plated and stained at relatively low density. Thus the substratum is not 
saturated with PAI-1 and it is possible to visualize the effect of TGFp on PAI-1 
protein expression.
Cells were counterstained with Texas Red-phalloidin to allow concurrent 
examination of filamentous actin (F-actin) content. PAI-1 staining was seen
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Fig. 16. Effect of Actin depolymerization on TGFP-induced PAI-1 protein 
expression. Serum-starved mesangial cells were treated with 1 mM CytB, 0.1 
pM LatB, 10 pM Y-27632 or 20 pM HA-1077 for 1-hour prior to 24-hour treatment 
with 10 ng/ml TGFp. The effect of actin depolymerization on PAI-1 protein 
expression was measured in conditioned media using Western blot analysis 
(n=3). (A) A representative Western blot showing increase in PAI-1 expression 
with TGFp treatment in serum-free media. (B) Inhibition of actin polymerization 
by agents using different mechanisms blocks basal and TGFp-induced PAI-1 
expression. The vertical bars and the error bard represent mean values for PAI-1 
protein and SEM respectively. The value for untreated control is set at 100%.
*: p<0.05 compared to S- control, **: p <0.005 compared to S- control, t :  P <0.05 
compared to TGFp treated control.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
83
F-Actin PAI-1
S-
TG Fp
TG Fp
+
CytB
TG Fp
+
Y-27632
MM
^^ Mi■1
Fig. 17. Effect of Actin depolymerization on TGFP-induced PAI-1 expression 
by immunocytochemistry. Serum-starved mesangial cells were treated with 1 
mM CytB (E, F) or 10 pM Y-27632 (G, H) before 24-hour treatment with 10 ng/ml 
TGFp (C-H). Cells were stained with Texas-Red phalloidin to visualize stress 
fibers (arrow) (A, C, E, G) and PAI-1 antibody (arrowhead) (B, D, F, H).
Phalloidin staining shows abundant stress fibers (red staining) in S- control (A) 
and TGFp treated (C) cells. TGFp treated cells show more intense staining for 
PAI-1 (green staining) (D) compared to S- control (B). Loss of stress fibers with 
cytoskeleton inhibitors (E, G) correlates with loss of staining for PAI-1 (G, H)
(n=1)-
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intracellularly and on the substratum. TGFp increased staining for PAI-1 after 24- 
hour treatment. Y-27632 and CytB reduced stress fiber content and staining for 
PAI-1 in both basal and TGF(3-stimulated conditions (Fig. 17). Thus PAI-1 
expression changes in parallel with changes in actin polymerization.
Stabilization of actin cvtoskeleton increases TGFB-induced PAI-1 expression 
The results showed that inhibition of actin polymerization inhibited basal 
as well as TGFp-induced PAI-1 expression. If the actin cytoskeleton controls PAI- 
1 expression, then an increase in actin fibers may increase PAI-1 expression. To 
test the possibility that stabilization of actin polymers can increase PAI-1 
expression, serum-starved cells were pre-treated for 1 hour with Jasplakinolide 
(JAS), an agent that increases the F-actin content of cells by directly binding to 
actin polymers and increasing nucleation. Cells were treated with 10 ng/ml TGFp 
for indicated time periods, with and without JAS. In contrast to the actin 
depolymerizing agents, JAS increased basal and TGFp-mediated PAI-1 mRNA 
expression to 154.3±14% and 142.7±10.3% of respective controls as determined 
by quantitative real-time RT PCR analysis (Fig. 14F). To ensure that the effects 
of JAS were mediated by increased F-actin content, cells were co-treated with 
JAS and actin depolymerizing agents in the presence or absence of TGFp (Fig. 
18). Co-treatment with CytB, Y-27632 or Toxin B depolymerized actin 
cytoskeleton and antagonized the JAS-mediated increase in PAI-1 mRNA to 
24.6±4.6%, 52.6±8.9% and 39.1±8.7% of their respective JAS-treated controls. 
CytB, Y-27632 or Toxin B also blocked JAS-mediated increase in TGFp-induced
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Fig. 18. Effect of changes in actin polymerization on TGFp-induced PAI-1 
mRNA expression. Serum-starved mesangial cells were treated with 50 nM JAS 
and, 1 mM CytB (A), 10 pM Y-27632 (B) or 10 pM Toxin B (C) for one hour prior 
to 8-hour treatment with 10 ng/ml TGFp (n=3). PAI-1 mRNA expression was 
measured using quantitative real-time PCR analysis. The vertical bars and the 
error bars represent mean PAI-1 mRNA values and SEM respectively. The value 
for untreated control is set at 100%. *: p<0.05 compared to S-, **: p<0.01 
compared to S-, ***: p<0.005 compared to S-, P< 0.05 compared to TGFp, 
t t f :  p<0.005 compared to TGFp, $: p<0.05 compared to JAS, #: p<0.05 
compared to TGFp+JAS, ###: p<0.005 compared to TGFp+JAS.
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Fig. 19. Effect of JAS and Toxin B mediated changes in actin 
polymerization on TGFp-induced PAI-1 protein expression. Serum-starved 
mesangial cells were treated with 50 nM JAS and 10 pM Toxin B for one hour 
prior to 24-hour treatment with 10 ng/ml TGFp. PAI-1 protein was measures in 
conditioned media using Western blot analysis. (A) Representative Western blot 
analysis of conditioned media for PAI-1 detection using Western blot analysis 
(n=3). (B) The vertical bars and the error bars represent mean PAI-1 protein 
values and SEM respectively. The value for untreated control is set at 100%. *: 
p<0.05 compared to S-, f .  p< 0.05 compared to TGFp, $: p<0.05 compared to 
JAS, #: p<0.05 compared to TGFp+JAS.
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increase in TGFp-induced PAI-1 mRNA expression; decreasing PAI-1 mRNA to 
17.9±1.1 %, 51.3±14.8% and 19.1±10.5% of TGFp+JAS-treated controls.
To confirm the effect of JAS on PAI-1 protein expression under the same 
conditions, cells were treated with combinations of TGFp, JAS and actin 
depolymerizing agents for 24 hours. Western blot analysis of conditioned media 
showed JAS increased basal and TGFp-induced PAI-1 protein to 148.5±5 % and
148.1 ±7.1 % of respective control at 24 hours. Inhibition of actin polymerization 
by Toxin B (Fig. 19), CytB (Fig. 20) and Y-27632 (Fig. 20) inhibited JAS- 
mediated increase in PAI-1 protein to 28.7±4.9%, 19.3±6.2% and 46.4±11.3% of 
their respective JAS-treated controls (Figs. 19, 20). At the same time, Toxin B, 
CytB and Y-27632 blocked JAS-mediated increase in TGFp-induced PAI-1 
protein expression to 18.9±3.4%, 13.1 ±2.9% and 29.1 ±7.6% of their respective 
TGFP+JAS-treated controls (Figs. 19, 20).
Table 4 shows representative calculation of the changes in PAI-1 cDNA 
concentration by real-time PCR analysis. The software automatically calculates 
the concentration based on the crossing point of each sample. The values for 
PAI-1 expression were normalized to the values for UBC, which remained 
relatively unaffected by the experimental conditions.
In summary, the bi-directional changes in actin polymerization were 
followed in the same direction by the changes in TGFp-mediated PAI-1 
expression. An increase in stress fiber content of the cells caused an increase in 
PAI-1 expression, whereas inhibition of actin polymerization caused inhibition of
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Fig. 20. Effect of changes in actin polymerization on TGFp-induced PAI-1 
protein expression. Serum-starved mesangial cells were treated with 50 nM 
JAS and, 1 mM CytB or 10 pM Y-27632 for one hour prior to 24-hour treatment 
with 10 ng/ml TGFp. PAI-1 protein expression was measured in conditioned 
media using Western blot analysis. (A) Representative Western blot analysis of 
conditioned media for PAI-1 detection using Western blot analysis (n=3). (B) The 
vertical bars and the error bars represent mean PAI-1 protein values and SEM 
respectively. The value for untreated control is set at 100%. *: p<0.05 compared 
to S-, t :  P< 0.05 compared to TGFp, p<0.05 compared to JAS, #: p<0.05 
compared to TGFp+JAS.
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Table 4. Calculation of PAI-1 cDNA concentration by real-time PCR
CONDITION
Cr.
Pt.
PAI-1
Calc.
Con.
(pg)
Cr.
Pt.
UBC
Calc.
Con.
(pg)
PAI-1 / 
UBC
(x1 O'5)
%
CONTROL
Serum - control 23.2 0.0118 20.2 234.2 5038 100.0
TGFp 20.9 0.0427 19.9 289.8 14734 292.4
JAS 22.6 0.0167 20.2 237.7 7025 139.4
TGFp + JAS 20.6 0.0501 19.9 288.5 17365 344.7
CytB 25.1 0.0041 19.8 306.4 1344 26.7
TGFp + CytB 23.8 0.0084 20.0 278.0 3025 60.0
JAS + CytB 26.3 0.0022 20.1 263.9 814 16.2
TGF + JAS + CytB 23.7 0.0087 19.8 301.7 2903 57.6
Toxin B 25.2 0.0039 20.1 254.2 1534 30.5
TGFp + Toxin B 22.5 0.0177 20.0 280.4 6312 125.3
JAS + Toxin B 24.9 0.0047 20.3 220.0 2113 42.0
TGFp + JAS + Toxin B 22.7 0.0156 20.2 247.0 6315 125.4
PAI-1 standard 23.5 0.0100 - - - -
UBC standard - - 21.5 100.0 - -
Abbreviations are: Cr. Pt, crossing point; Calc. Con, calculated concentration.
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PAI-1 expression. The inhibition of actin polymerization also prevented actin 
stabilization by JAS.
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CHAPTER 6
EFFECT OF ACTIN CYTOSKELETON ON THE PAI-1 PROMOTER 
Introduction
The results discussed in previous chapter showed that the changes in 
actin polymerization regulated PAI-1 mRNA and protein expression. The 
mechanism of this regulation was examined next.
The expression of PAI-1 is tightly regulated by a variety of cytokines, 
growth factors, hormones and other agonists [78], These agents include TGFp, 
Angiotensin II, thrombin, glucocorticoids, tumor necrosis factor-a and endotoxin 
[78,135]. The regulation of PAI-1 mRNA expression is primarily at the level of 
transcription [136, 137], Functional analysis of the regulatory region of the PAI-1 
promoter shows the presence of multiple regulatory elements that respond to 
diverse stimuli listed above [79]. Schematic representation of selected consensus 
sequences in human PAI-1 promoter is shown in fig. 21 [69, 76, 115]. The human 
PAI-1 promoter has at least 3 AP-1 sites in its distal promoter region (-800 to -  
636) and one in the proximal promoter region (-81 to -75) [78], These AP-1 sites 
are critical for induction of PAI-1 by the agents listed above [78, 138]. The 
regulation of PAI-1 promoter by TGFp has been extensively studied [135, 78, 
139]. Two TGFP-inducible, cis-acting regulatory elements were first identified in 
the 5’ flanking DNA of the human PAI-1 gene; a relatively strong element 
between -791 and -328, and a weaker element between -328 and -187
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[139]. Later, three SMAD-binding sites were identified between -794 and -  532 
that were sufficient for induction by TGF(3 [140]. PAI-1 promoter also contains 
NF-1 like sequences, one p53 binding site between -139 and -160 [141], two 
glucocorticoid response elements (GREs) between -100 and +75, and -800 and 
-549 [76], CRE, five Hypoxia Responsive Elements (HREs) [142] and two Sp1 
binding site-like sequences at -72 to -67 and -45 to -40 [143]. The rat PAI-1 
gene shares many structural similarities with the human PAI-1 gene and contains 
similar regulatory elements in the promoter [144], For example, the rat PAI-1 
promoter contains binding sites for AP-1 and Sp1, glucocorticoids response 
elements and CRE. Although the rat and human PAI-1 promoter are similar, the 
number of each type of regulatory elements may be different. For example, the 
rat PAI-1 promoter contains five GREs as compared to two contained in the 
human PAI-1 promoter. Also, the rat PAI-1 promoter contains two regions that 
have at least 80% sequence similarities to its human counterpart. The first is 
between -91 and TATA box, and the second between -800 and -549.
The serum response factor (SRF), a transcription factor, has been shown 
to mediate effects of changes in actin cytoskeleton on expression of some genes
[145]. AP-1-dependent genes are direct targets of SRF. For example, inhibition of 
actin polymerization by inhibitors of direct and Rho-mediated polymerization 
blocked inducible nitric oxide gene expression in human epithelial cells [145]. 
Similarly, inhibition of Rho by C3 toxin blocked activation of AP-1 in rat-1 cells
[146]. TGF(3-mediated SMAD 2/3 activation also required Rho signaling in human 
breast carcinoma cells [147]. Thus, the evidence from the literature suggests a
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role for Rho and actin cytoskeleton in regulation of genes through similar 
regulatory elements as contained in PAI-1 promoter. The hypothesis that Rho- 
mediated changes in actin polymerization regulate TGFp-induced PAI-1 
expression at the promoter level was therefore examined.
Experimental Model
To examine if PAI-1 expression was at the transcriptional level, the human 
PAI-1 promoter, spanning -973 to +133 nucleotides, was cloned into a luciferase 
vector as described in chapter 2. Human and rat mesangial cells were serum- 
starved and transfected with human PAI-1 promoter vector for 24 hours. Cells 
were then pre-treated with CytB to inhibit actin polymerization followed by 
treatment with TGFp. The effect on promoter activity was determined by 
luciferase assay.
Results
TGFS induces PAI-1 promoter activity in rat mesangial cells
The initial time-course analysis of the effect of TGFp on PAI-1 promoter 
activity was conducted in rat mesangial cells due to their better transfection 
efficiency. Rat mesangial cells (p27) were co-transfected with PAI-1 promoter 
vector and renilla luciferase vector in serum-free media. After 24 hours, the cells 
were treated in triplicate wells with 10 ng/ml TGFp (dose shown to be effective on 
PAI-1 mRNA and protein expression) for varying amounts of time to identify the 
time-point for the maximum increase in PAI-1 promoter activity. In a single 
experiment, TGFp-treatment for 2, 4, 6, 8 and 24 hours increased PAI-1 
promoter activity to 108.4±3.7% 124.2±7.7%, 128.5±3.1%, 109.0±3.9% and
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Fig. 22. Time-course analysis of TGFp on PAI-1 promoter activity. Rat
mesangial cells were co-transfected with PAI-1 promoter plasmid and renilla 
luciferase plasmid in serum-free media. After 24 hours, 10 ng/ml TGFp was 
added to the media for the indicated times. Duplicate wells of control cells in 
serum-free media and triplicate cells of TGFp-tread cells were used for the 
experiment. Luciferase activities in samples were measured using dual luciferase 
assay (n=1). Each bar represent average luciferase activity for PAI-1 promoter 
normalized to renilla luciferase activity in the same sample. The normalized 
Luciferase activity of time-matched untreated control is set as 100%.
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116.6±4.2% of their respective time-matched controls. The values for renilla 
luciferase activities were above background and hence were used to normalize 
for transfection efficiency.
The effect of TGFp was maximum at 6-hours with the minimum variation.
In the following set of experiments, cells were treated with TGFP for 6 hours. 
Inhibition of actin polymerization blocks TGFS-induced PAI-1 promoter activity
In rat mesangial cells, the effect of TGFp on PAI-1 promoter (128.5 %) 
was much smaller than the effects on PAI-1 mRNA (~250%) and protein (~250%) 
in human mesangial cells. Therefore the remaining experiments were performed 
in human cells. Serum-starved mesangial cells were transfected with PAI-1 and 
renilla luciferase plasmid as described above. After 24 hours, cells were pre­
treated with 1 pM CytB followed by 10 ng/ml TGFp for six hours. Since, co­
transfection with renilla luciferase was not successful, luciferase counts were 
normalized to the protein concentration. Previously, Owens et al showed 
normalization for protein concentration as an acceptable method for 
normalization for transfection efficiency [148, 149], The treatment with TGFp 
increased PAI-1 promoter to 293.6±36.5% of control. CytB inhibited basal as well 
as TGFp-induced PAI-1 expression to 45.1 ±6.1% and 34.6±12.7% of their 
respective controls. The effects of other cytoskeleton inhibitors could not be 
determined due to limited transfection efficiency.
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Fig. 23. The effects of TGFp and actin depolymerization on human PAI-1 
promoter activity. Human mesangial cells were co-transfected at 60-80% 
confluence with 1 pg human PAI-1 promoter-containing plasmid and 1 pg renilla 
luciferase plasmid. The cells were serum-starved at the time of transfection.
After three hours of transfection, CytB was added to appropriate wells. After 24 
hours, cells were treated with 10 ng/ml TGFp for 6 hours. Luciferase activity was 
normalized for the protein concentration of each sample to get the activity in 
counts/mg protein for each sample. For each treatment, cells were transfected at 
least in duplicates (n=3). Each bar represent average luciferase activity for PAI-1 
promoter normalized to cellular protein concentration. The normalized Luciferase 
activity of untreated control is set as 100%. *: p<0.05 compared to S-, t :  P< 0.05 
compared to TGFp.
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CHAPTER 7
EFFECTS OF TGFp AND ACTIN CYTOSKELETON ON PLASMINOGEN
ACTIVATORS
Introduction
The effects of TGFP and actin cytoskeleton on PAI-1 expression were 
determined as shown in chapters 4 to 6. Next, the effects of cytoskeleton 
disruption on two other components of plasminogen activator system namely 
tissue- (tPA) and urokinase- (uPA) type plasminogen activators were examined.
Two activators (tPA, uPA) and one inhibitor (PAI-1) of plasminogen 
activation constitute the plasminogen activator system, which regulates ECM 
degradation. The mesangial extracellular matrix determines the physical, 
mechanical and functional properties of glomerulus in normal and pathological 
conditions [57], Plasminogen activators convert inactive plasminogen into active 
plasminogen. Plasmin activates matrix metalloproteinases (MMPs), which then 
digest ECM. Plasmin itself has some matrix digesting activity. PAI-1 binds to tPA 
and uPA, and blocks the activation of plasminogen into plasmin. Thus, tPA and 
uPA favor ECM degradation whereas PAI-1 favors ECM deposition. The balance 
between plasminogen activators and PAI-1 thus determines the rate and the 
amount of ECM deposition.
The DNA array analysis showed a 2.8-fold increase in tPA expression 
upon actin depolymerization (Table 3, Chapter 3), suggesting a coordinated 
regulation of the plasminogen activator system by the actin cytoskeleton. The
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effects on uPA still remained to be examined. Moreover, treatment with TGFp is 
shown to have varying effects on the expression of plasminogen activators 
depending on the cell-type [61, 124, 150-152], The following set of experiments 
was therefore performed to understand the role of TGFP and the actin 
cytoskeleton on the regulation of plasminogen activator system as a whole. 
Experimental Model
Serum-starved human mesangial cells were treated with 10 ng/ml TGFp 
for 4, 8, 24 and 48 hours to determine optimum treatment duration. The changes 
in tPA and uPA mRNA expression were examined by real-time quantitative PCR 
analysis. In subsequent experiments cells were pre-treated with CytB, LatB or Y- 
27632 for one hour to inhibit actin polymerization, followed by 8-hour treatment 
with TGFp. These treatment conditions were identical to those used to examine 
the effects on PAI-1 expression in earlier chapters. The effect of TGFp and actin 
depolymerization on tPA and uPA expression was determined at the mRNA 
level. Real-time PCR analysis was used to detect changes in tPA and uPA 
mRNA expression. The changes in tPA and uPA protein expression were 
examined in conditioned media at 24 hours to match the experimental conditions 
used for PAI-1 protein using Western blot analysis.
Results
Quantification of tPA and uPA mRNA expression by real-time PCR analysis
The existing literature show conflicting evidence about production of tPA 
and uPA by human mesangial cells and the regulation of plasminogen activator 
system by TGFp [61, 89, 152-158]. Therefore, the expression of uPA and tPA
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mRNA by serum-starved mesangial cells was confirmed first prior to examining 
the effect of TGF(3 on tPA and uPA expression. Using real-time PCR detection, 
both uPA and tPA mRNAs were successfully detected in human mesangial cells. 
Briefly, a reverse transcription reaction on thermocycler (MJ Research, Reno,
NV) was followed by a quantitative real-time PCR analysis on Roche lightcycler 
(Roche Diagnostics, Indianapolis, IN). First, standard curves fortPA (Fig. 24) and 
uPA (Fig. 25) cDNA were generated using known concentrations of cDNA 
templates as described in chapter 2. The products of standard curve polymerase 
chain reactions were analyzed by gel electrophoresis to ensure amplification of a 
single, specific product (Fig. 26).
Subsequently, one known concentration of standard (0.001 pg for tPA and 
0.0001 pg for uPA) was amplified along with experimental samples. The values 
for tPA and uPA concentrations were derived in picograms, which were further 
normalized to similarly obtained values for a reference gene, Ubiquitin (UBC), in 
each sample. The sample concentrations were calculated by the software by 
comparing the crossing point of experimental sample with that of the known 
standard normalized to previously saved standard curve as described in chapters 
2 and 4. Ubiquitin was used as the reference gene to normalize the 
concentrations for tPA and uPA. Figures 27 and 28 show amplification (panel A), 
melting curve analysis (panel B), melting peak analysis (panel C) and gel 
electrophoresis (panel D) of tPA and uPA respectively from representative 
experimental samples.
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Fig. 24. tPA standard curve for real-time PCR analysis. (A) Amplification of 
tPA cDNA plotted as fluorescence vs. cycle number. Each sample is represented 
in a uniquely colored line on the real-time PCR software, allowing tracing of 
amplification of individual samples. (B) tPA standard curve plotted as cycle 
number vs. log concentration showing a linear standard curve (r= -1). (C) Real­
time monitoring of melting curve analysis of PCR products plotted as 
fluorescence vs. cycle number showing only one PCR product corresponding to 
tPA. (D) Melting curve analysis data plotted as changes in fluorescence signal 
over time (dF/dT) vs. temperature. Presence of only one melting peak in this 
reaction corresponding to melting temperatures of tPA (~85.5°C) indicates 
specificity of the amplification reaction and absence of primer-dimers.
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Fig. 25. uPA standard curve for real-time RT-PCR analysis. (A) Amplification 
of uPA plotted as fluorescence vs. cycle number. Each sample is represented in 
a uniquely colored line on the real-time PCR software, allowing tracing of 
amplification of individual samples. (B) uPA standard curve plotted as cycle 
number vs. log concentration showing a linear standard curve (r= -1). (C) Real­
time monitoring of melting curve analysis of PCR products plotted as 
fluorescence vs. cycle number showing only one PCR product corresponding to 
uPA. (D) Melting curve analysis data plotted as changes in fluorescence signal 
over time (dF/dT) vs. temperature. Presence of only one melting peak in this 
reaction corresponding to melting temperatures of PAI-1 (-83.5 C) indicates 
specificity of the amplification reaction and absence of primer-dimers.
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Fig. 26. Gel-electrophoresis of tPA and uPA standard curve PCR products.
Aliquots of PCR products (2 pi out of 20 pi total) were run on 8% acrylamide gel 
followed by ethidium bromide staining. (A) tPA and (B) uPA PCR products show 
a single band at expected base-pair location confirming specific amplification of 
respective templates.
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Fig. 27. Representative images from real-time PCR of tPA and UBC from 
experimental samples. (A) Amplification of tPA and UBC plotted as 
fluorescence vs. cycle number. Each line is represented in different color on the 
real-time PCR software, allowing tracing of amplification of individual samples. 
The crossing points for both tPA and UBC fall within the bars marking 
approximately cycles 15 and 22. (B) Real-time monitoring of melting curve 
analysis of PCR products plotted as fluorescence vs. cycle number showing two 
PCR products corresponding to tPA and UBC. (C) Melting curve analysis data 
plotted as changes in fluorescence signal overtime (dF/dT) vs. temperature. 
Presence of only two melting peaks in this reaction corresponding to melting 
temperatures of UBC (~82°C) and tPA (~85.5°C) indicate specificity of the 
amplification reaction and absence of primer-dimers. (D) Gel electrophoresis of 
PCR products from representative experimental samples show a single PCR 
product of expected base-pair size in each reaction.
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Fig. 28. Representative images from real-time PCR of uPA and UBC from 
experimental samples. (A) Amplification of uPA and UBC plotted as 
fluorescence vs. cycle number. Each line is represented in different color on the 
real-time PCR software, allowing tracing of amplification of individual samples. 
The crossing points for uPA and UBC fall within the bars marking approximately 
cycles 23-28 and 15-19 respectively. (B) Real-time monitoring of melting curve 
analysis of PCR products plotted as fluorescence vs. cycle number showing two 
PCR products corresponding to uPA and UBC. (C) Melting curve analysis data 
plotted as changes in fluorescence signal overtime (dF/dT) vs. temperature. 
Presence of only two melting peaks in this reaction corresponding to melting 
temperatures of UBC (~82°C) and uPA (~83.5°C) indicate specificity of the 
amplification reaction and absence of primer-dimers. (D) Gel electrophoresis of 
PCR products from representative experimental samples show a single PCR 
product of expected base-pair size in each reaction.
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TGFB has opposite effects on tPA and uPA mRNA expression
In previous experiments, the effective dose of TGFp was determined to be 
at 10 ng/ml (chapter 4). In a time- course analysis 10 ng/ml TGFp treatment 
increased uPA mRNA levels to 117.8%, 207.2%, 137.9% and 35.4% of 
respective time-matched control at 4, 8, 24 and 48 hours (n=1) (Fig. 29). 
Whereas, 10 ng/ml TGFp inhibited average tPA mRNA to 89.3%, 69.5%, 70.65 
and 28.8% of respective time-matched control at 4, 8, 24 and 48 hours (n=2)
(Fig. 29). Thus, TGFP increased uPA mRNA expression maximally at 8 hours.
On the contrary, TGFp inhibited tPA mRNA expression at most of the time points 
examined. Maximum increase in PAI-1 mRNA was seen at 8-hours (chapter 4) 
which corresponds to maximum increase in uPA expression and consistent 
inhibition of tPA expression at 8 hours. Therefore 8 hours was determined to be 
an optimum time-point for TGFp treatment.
Actin depolvmerization regulates tPA and uPA mRNA expression
The rate of plasminogen activation depends on the balance between 
plasminogen activators and PAI-1. Therefore the effects of inhibiting actin 
polymerization on expression of the plasminogen activators was examined first in 
order to understand the potential net effect on plasminogen activation. The 
samples from the same experiments in which actin depolymerization had shown 
inhibition of TGFp-induced PAI-1 expression were examined for tPA and uPA 
mRNA expression using quantitative real-time PCR analysis. In three separate 
experiments, TGFp decreased tPA mRNA expression slightly, but significantly, to 
80.7 ± 5.5% of untreated control (p<0.05), consistent with the profibrotic effects
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Fig. 29. Time-course analysis of TGFp-treatment on tPA and uPA mRNA 
expression. Human mesangial cells at 60-80% confluence were serum starved 
for 24 hours. Cells were treated with 10 ng/ml TGFp for 4, 8, 24 and 48 hours. At 
each time point, the effect of TGFp treatment on tPA (A) and uPA (B) mRNA was 
measured by real-time PCR analysis. (A) TGFp inhibited tPA mRNA at all the 
time-points examined (n=2). Each bar represent mean value for tPA expression. 
The ends of error bars represent the value for each of the two experiments. (B) 
TGFp treatment maximally increased uPA mRNA at 8 hours (n=1).
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of TGFp (Fig. 30). Actin depolymerization by Y-27632, CytB and LatB increased 
basal tPA expression to 232 ± 22.3%, 195.4 ± 26.7% and 288.9 ± 29.8% of 
untreated controls. Actin depolymerization also effectively reversed the inhibitory 
effects of TGFp on tPA expression. Y-27632, CytB and LatB increased tPA 
mRNA to 260.9 ± 22.6%, 208.3 ± 33.8% and 244.9 ± 39% of their respective 
TGFP-treated controls. This suggests that actin depolymerization coordinately 
regulates the plasminogen activator system. Actin depolymerization 
simultaneously inhibits PAI-1 expression and increases tPA expression, the net 
result of which favors activation of plasminogen activation and degradation of 
extracellular matrix. In contrast, TGFp increased uPA expression by 
246.7±61.4% of control (p<0.05). Inhibition of actin polymerization by CytB and 
Y-27632 changed uPA mRNA expression to 259.1 ± 119% and 115.6 ± 24.5% of 
respective controls under serum-free conditions. In the presence of TGFP, CytB 
and Y-27632 changed uPA mRNA expression to 95.8 ± 37.7% and 77.7 ± 16.3% 
of TGFP-treated control respectively. The effect of CytB and Y-27632 were not 
statistically significant (Fig. 31). In summary, TGFp increased uPA mRNA 
expression, whereas actin depolymerization did not have a statistically significant 
effect on the same.
Effect TGFB and actin depolvmerization on plasminogen activators protein 
expression
Since tPA and uPA are secreted upon synthesis, changes in tPA and uPA 
were determined by analyzing conditioned media using Western blot analysis. 
Neither tPA nor uPA proteins could be detected in conditioned media using
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Fig. 30. The effects of TGFP and actin depolymerization on tPA mRNA 
expression. Human mesangial cells at 60-80% confluence were serum starved 
for 24 hours. Cells were then pre-treated for one hour with 1.0 mM CytB, 0.1 pM 
LatB or 10 pM Y-27632 to inhibit actin polymerization. TGFP (10 ng/ml) was 
added to the media for next 8 hours. At the end of 8-hour treatment with TGFp, 
mRNA was isolated and analyzed by quantitative real-time PCR analysis for tPA 
mRNA expression (n=3). The vertical bars and the error bars represent mean 
tPA mRNA value and SEM respectively, The value for untreated control is set as 
100% *: p<0.05 compared to S-, t :  p<0.05 compared to TGFp, t t t -  P<0.005 
compared to TGFp.
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Fig. 31. The effects of TGFp and actin depolymerization on uPA mRNA 
expression. Human mesangial cells at 60-80% confluence were serum starved 
for 24 hours. Cells were then pre-treated for one hour with 1.0 mM CytB or 10 pM 
Y-27632 to inhibit actin polymerization. TGFp (10 ng/ml) was added to the media 
for next 8 hours. At the end of 8-hour treatment with TGFp, mRNA was isolated 
and analyzed by quantitative real-time PCR analysis for uPA mRNA expression 
(n = 5). The vertical bars and the error bars represent mean uPA mRNA value 
and SEM respectively, The value for untreated control is set as 100%. *: p<0.05 
compared to S - .
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Western blot analysis. Multiple optimization efforts including using smaller 
amounts of media for incubation (to reduce dilution of secreted tPA and uPA), 
using larger amounts of media for detection, concentrating the media using spin 
concentrators and using varying amounts of primary antibodies were 
unsuccessful in detecting tPA and uPA proteins in conditioned media. Previously 
uPA was successfully detected in this lab in a preparation of substratum attached 
extracellular matrix and membrane proteins called adhesion plaques but not in 
conditioned media [159, 160].
In summary, the results show an increase in tPA mRNA expression by 
actin depolymerization. PAI-1 expression was inhibited under similar 
experimental conditions, suggesting a coordinated regulation of these two genes 
with opposite functions by actin cytoskeleton.
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CHAPTER 8 
DISCUSSION 
Mesangial myofibroblast activation as a disease model
Diverse cells and tissues react to injury with similar responses, including 
myofibroblast differentiation and formation of scar tissue from increased 
extracellular matrix accumulation [22-24, 29, 161-166]. In the event of tissue 
injury, native fibroblasts or mesenchymal cells with fibroblast-like properties can 
transdifferentiate into activated myofibroblasts. De novo expression of genes, 
possibly required to cope with demands of injury and tissue repair, is seen upon 
myofibroblast differentiation [19, 119, 167], For example, the activation of a-SMA 
expression, a property associated with smooth muscle phenotype and hence the 
name myofibroblast, is a common feature of myofibroblasts regardless of the 
tissue affected [168], In the skin, dermal fibroblasts transdifferentiate into 
myofibroblast during the process of wound healing and start expressing a-SMA 
de novo [11]. Similarly, in the kidneys, glomerular mesangial cells, mesenchymal 
cells that hold the capillary tufts of glomeruli together, do not normally express a- 
SMA. But in the event of injury, the activated mesangial cells transdifferentiate 
into myofibroblasts and start expressing a-SMA [19]. They also undergo 
hypertrophy to meet the functional demands in disease states [168]. Hypertrophic 
cells also produce more ECM proteins leading to scar tissue formation. Indeed, 
myofibroblast differentiation is associated with excess ECM deposition in 
glomeruli in chronic glomerulosclerotic diseases [165]. The association of the
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myofibroblast differentiation with ECM deposition and scarring suggests that the 
knowledge of the mechanisms that regulate myofibroblast differentiation may 
provide new insights into the cellular processes that control tissue scarring. The 
overall objective of the current study was to identify the mechanisms regulating 
myofibroblast differentiation. In this study, the role of actin cytoskeleton in the 
regulation of gene expression and phenotype changes in glomerular mesangial 
cells was examined.
Cultured mesangial cells as the experimental model of myofibroblast 
differentiation
Previously, Glass et al showed that cultured mesangial cells mimic in vivo 
changes during myofibroblast activation[26]. Initial culture in presence of serum 
causes mesangial cell proliferation similar to that seen in early stages of 
glomerular injury. Whereas, in the absence of serum, the mesangial cells stop 
proliferating, spread more, become hypertrophic, increase their stress fibers, and 
express more a-SMA [26], The phenotype seen during the serum-deprivation 
closely resembles that of myofibroblasts seen in the later stages of glomerular 
injury. Thus, the cultured mesangial cells share similarities both in phenotypes 
and in the sequence of phenotype changes with in vivo myofibroblasts. 
Therefore, cultured mesangial cells serve as a good model system to study the 
myofibroblast phenotype in vitro.
Primary culture human mesangial cells between passages 5 and 9 were 
therefore used in the current study to understand the regulation of myofibroblast 
differentiation. The serum-free media was used as the basal culture condition to
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allow the mesangial cells to acquire myofibroblast-like phenotype. The use of 
already activated mesangial cells resembles the clinical scenario in chronic 
glomerular diseases, where a majority of the patients present with already 
established glomerular lesions containing activated mesangial cells. Also, the 
role of individual growth factor can be studied when added to the serum-free 
media used as the basal culture condition.
Actin cytoskeleton as a regulator of gene expression
The concordant increase in stress fiber formation with a-SMA expression 
and hypertrophy in serum-starved mesangial cells lead to the hypothesis that the 
actin cytoskeleton regulates a-SMA expression and hypertrophy in mesangial 
cells. In a further study, the use of agents that modulate actin cytoskeleton 
showed that the changes in actin cytoskeleton regulated both hypertrophy and a- 
SMA expression in serum-starved mesangial cells [28], The a-SMA expression 
was regulated at the level of transcription and message stability. These findings 
were consistent with the regulation of a-SMA mRNA by the actin cytoskeleton in 
different cell types [169, 149]. These results showed the evidence for the role of 
actin cytoskeleton in gene regulation and myofibroblast-differentiation in 
mesangial cells.
Since cellular hypertrophy is associated with an increase in global protein 
synthesis, it was hypothesized that the actin cytoskeleton regulates myofibroblast 
phenotype by simultaneously regulating the expression of multiple genes. Recent 
availability of DNA arrays containing multiple genes with related functions on one 
array provides opportunity to study the expression of multiple genes
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simultaneously. Since the myofibroblast differentiation is associated with 
increased ECM, the effects of actin cytoskeleton on a DNA array containing 
genes related to ECM and cell-interaction were examined.
The array experiment way performed only once, but the results were 
consistent with the hypothesis that cytoskeletal organization coordinately 
regulates genes involved in myofibroblast function and sclerosis. Also the results 
were confirmed, in particular, for PAI-1 and tPA. The expression of 74 out of 265 
genes was detected on the array (Chapter 3). Cell-type specific and/or cell- 
culture conditions could account for the detection of limited number of genes. 
Alternatively, optimization of the protocol could help detect some of the genes not 
detected in this study. Also, repeating the experiment with the same and other 
actin depolymerizing agents could show the consistency of changes in pattern of 
gene expression.
A noticeable pattern of gene expression was observed among the 
detected genes. Out often down-regulated genes, four were precursors of 
extracellular matrix components, namely procollagen 3 a1 subunit, procollagen 1 
a2 subunit, collagen 4 a2 subunit and fibronectin. Endothelial plasminogen 
activator inhibitor-1 (PAI-1) precursor also decreased. Since the role of PAI-1 is 
to favor ECM deposition, a decrease in PAI-1 would also decrease ECM. Thus 
actin depolymerization decreases both ECM components as well as profibrotic 
regulators of ECM turnover. The collective effect is a decrease in ECM 
deposition. Thus, actin depolymerization correlates with decreased PAI-1 
expression and ECM deposition. Since, PAI-1 expression is an attribute of
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myofibroblast differentiation and the ECM deposition is an outcome of such 
differentiation, these findings support the overall hypothesis that changes in actin 
polymerization regulate the myofibroblast phenotype of mesangial cells.
At the same time, out of four genes that increased, three favor 
degradation of ECM. These include tissue-type plasminogen activator (tPA), 
decorin (DCN) and matrix metalloproteinases 11 (MMP 11). tPA converts inactive 
plasminogen into active plasmin with fibrolytic properties [56]. MMP11, although 
not a major fibrolytic enzyme, digests ECM under certain conditions [170].
Decorin inhibits profibrotic TGFp and thereby prevents deposition of ECM [122, 
171]. Together these genes lead to increased removal of ECM.
The cut-off ratios for increase (>2-fold) or decrease (>50%) in gene 
expression set during the DNA array analysis were arbitrarily selected, requiring 
further validation of the findings. Also, the experiment was performed only once. 
Thus, further validation of the changes in gene expression seen on DNA array 
was required. Therefore, the changes in the expression of two genes, relevant to 
myofibroblast differentiation and ECM regulation, seen on DNA arrays were 
confirmed by Northern blot and Western blot analysis. The components of 
plasminogen activator system, PAI-1 and tPA, were selected for the confirmation 
first since they are the major regulators of fibrinolysis and are directly related to 
ECM turnover. Also they both were regulated in opposite directions by actin 
cytoskeleton consistent with their opposite functions on ECM. The findings on 
PAI-1 and tPA were confirmed at mRNA and protein levels, providing strong 
evidence for coordinated gene regulation by the actin cytoskeleton. Indeed,
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inhibition of actin depolymerization by CytB and Y-27632 inhibited PAI-1 mRNA 
and protein expression, whereas CytB increased tPA protein expression. Thus 
the findings of DNA array experiments were reflected at the protein level. These 
experiments were set under different cell-culture conditions, some in the 
presence of serum and some in the absence of serum, making the comparison of 
results difficult. The aim of the next set of experiments was to understand the 
significance of regulation of PAI-1 and tPA in the context of their 
pathophysiological regulation using a uniform cell culture condition.
TGFp induction of PAI-1 expression
Since PAI-1 is a major mediator of the ability of TGFp to cause fibrosis 
[172] and it acts as a gate-keeper of the plasminogen activation cascade by 
inhibiting both tPA and uPA, the regulation of PAI-1 expression was studied first 
and more extensively than that of tPA or uPA. The cells were treated with TGFp, 
a major regulator of PAI-1, plasminogen activator, ECM turnover and 
myofibroblast differentiation; to resemble in vivo regulation of plasminogen 
activator system. The effect of actin cytoskeleton on TGFp-mediated expression 
of the plasminogen activator system was studied in human mesangial cells. The 
use of TGFp as an agonist provides a model that mimics in vivo regulation of 
plasminogen activators, and helps to understand myofibroblast differentiation and 
ECM regulation.
The dose-response analyses of TGFp on PAI-1 mRNA and protein 
expression were performed first (Chapter 4). Although treatment with 1 ,2 ,5  and 
7.5 ng/ml TGFP increased average PAI-1 mRNA expression to 381.9%, 323.1%,
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protein were inconsistent at these lower doses. At 10 ng/ml, TGFp increased 
both PAI-1 mRNA and protein expression to 287.9% and 283.6% of respective 
controls. Additionally, this concentration is very commonly used in published 
studies by numerous investigators. In a similar dose-response analysis, Motojima 
et al also found 10 ng/ml as the most effective dose of TGFP for PAI-1 induction 
in rat mesangial cells [82]. Other researchers in this lab have also used TGFp 
successfully at 10 ng/ml for studying effect on COX-2 expression (Harding et al, 
unpublished observations). Also, this concentration of TGFp is pathological which 
makes the experiments more relevant to an actual pathological state [126]. The 
failure to show an increase with lower doses of PAI-1 expression was difficult to 
interpret since the experiment was performed only once. It may result from 
inefficient translation and/or secretion of PAI-1, inactivation of lower doses of 
TGFp in the treatment media at 24-hour treatment or lack of activation of co­
stimulatory pathways.
The time-course analysis showed that TGFP increased PAI-1 mRNA 
maximally to a value of 191.0 ± 23.5% at 8 hours (Chapter 4). PAI-1 mRNA 
decreased to 100.1 ± 13.5% and 90.6 ± 8.7% of time-matched controls at 24 and 
48 hours respectively suggesting either loss of TGFP activity or inhibition of 
TGFp activity at those time points. Although not tested directly at protein level, 
the array experiment did show presence of decorin mRNA, a known inhibitor of 
TGFp [122]. The analysis for PAI-1 protein showed maximum activation at 24 
hours. At earlier time-points PAI-1 could not be detected in the conditioned
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media. Since PAI-1 is a secreted protein, there may be a lag period before PAI-1 
is synthesized and secreted in sufficient amounts to reach the level of detection 
in the culture media. Even using a more sensitive detection method such as 
enzyme-linked immunosorbent assay (ELISA), Matsumoto et al found 24 hr 
treatment with TGF(3 to maximally induce PAI-1 protein expression [127], 
Therefore, the use of more sensitive detection method may still show 24 hours as 
optimum duration of treatment. Although PAI-1 is a rapidly secreted protein, 
protein synthesis takes longer than mRNA synthesis, partially accounting for the 
differences in the time-frame of their detection. Therefore, PAI-1 mRNA reached 
a peak at 8 hours and protein reached a peak at 24 hours. At 48 hours, PAI-1 
protein was still elevated (146%), whereas mRNA returned to the control levels 
(90.6 ± 8.7%). Alternatively, this sustained increase at 48 hours in protein 
expression could represent accumulation in the media. Since a consistent and 
comparable increase was seen in PAI-1 mRNA at 8 hours and protein at 24 
hours, these time points were used for subsequent experiments.
Inhibition of actin cytoskeleton on TGFp-induced PAI-1 expression
In vivo and in vitro evidence suggest that Rho and the actin cytoskeleton 
regulate PAI-1 expression and matrix deposition. The small GTPase, Rho, is 
known to regulate expression of PAI-1 [81, 108, 173, 174], Also, inhibition of Rho 
signaling prevents fibrosis in animal models, an effect consistent with PAI-1 
inhibition [102-104], Since one of the major functions of Rho is to regulate actin 
polymerization, the effects of Rho on PAI-1 expression could be mediated 
through the actin cytoskeleton. Secondly, activated mesangial cells or
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myofibroblasts express a-SMA and PAI-1 de novo in various forms of renal 
fibrosis. Recently this lab showed that Rho-mediated changes in actin 
polymerization regulate a-SMA expression and hypertrophy, both attributes of 
myofibroblast differentiation, in mesangial cells [28], Although the injurious 
agents and cytokines involved are diverse, it is likely that common cellular 
mechanisms underlie the regulation of myofibroblast differentiation and increased 
ECM deposition common to sclerotic diseases. PAI-1, another attribute of 
myofibroblast differentiation, could also be similarly regulated by the changes in 
actin polymerization. Thus two separate lines of evidence suggest the role of 
actin cytoskeleton in the regulation of PAI-1 expression. Therefore the hypothesis 
that Rho GTPase regulates PAI-1 expression by modulating actin polymerization 
was examined.
To test the hypothesis, the effects of either inhibition of Rho-mediated 
signaling or direct inhibition of actin polymerization was examined on TGFp- 
induced PAI-1 mRNA and protein expression (Chapter 5). The inhibition of Rho 
blocked both basal and TGF(3-induced PAI-1 mRNA expression in human 
mesangial cells. Similarly, direct inhibition of actin polymerization with CytB and 
LatB also inhibited basal and TGF(3-induced PAI-1 mRNA expression. The 
results seen by real-time PCR were comparable to those seen by conventional 
methods such as Northern blot analysis. These confirmed the utility of real-time 
quantitative PCR in detecting changes in mRNA expression. Since the effects of 
Rho inhibition on PAI-1 mRNA expression are mimicked by direct inhibition of
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actin polymerization, it suggests that the effects of Rho on PAI-1 mRNA 
expression are mediated by changes in actin polymerization.
Surprisingly, TGFP did not show any effect on PAI-1 expression in cell- 
lysates. Since PAI-1 is rapidly secreted upon synthesis, the induction by PAI-1 
may only be reflected in secreted PAI-1. The secreted PAI-1 binds to the 
substratum on tissue culture dishes and saturates the binding sites on the 
substratum. The cell-lysates were prepared by scraping adherent cells. The 
lysates generated in this manner include both intracellular and substrate-bound 
extracellular PAI-1 and hence may not show a true representation of changes in 
protein expression. The Western blot showed specific inhibition of the PAI-1 band 
with CytB treatment, whereas the other non-specific bands seen on the blot 
remained constant. This suggests that CytB is not affecting the secretion of PAI-1 
in which case an increased intracellular PAI-1 would have been seen. However, 
since the cell scrapings contain both intracellular and the substratum-bound PAI- 
1, which is generally saturated at the cell density used in this study, these 
differences were masked on cell-scrappings. CytB treatment blocked PAI-1 
expression in both cell-lysates and conditioned media suggesting that the 
inhibition was at the level of protein synthesis or earlier at the mRNA level. 
Subsequently, the conditioned cell culture media containing the secreted proteins 
was used to detect the changes in PAI-1 protein expression. The changes in PAI- 
1 protein expression upon treatment with agents that increase or decrease actin 
polymerization were consistent with the changes in PAI-1 mRNA expression 
under similar treatment conditions.
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The changes in actin cytoskeleton upon treatment under the experimental 
conditions examined above were visualized by staining with Texas-red labeled 
phalloidin, an agent that binds polymerized F-actin fibers (Chapter 5). Treatment 
with Y-27632 and CytB showed loss of abundant stress fibers seen under control 
conditions. Simultaneous immunostaining of the same cells for PAI-1 antigen 
showed inhibition of PAI-1 expression in cells with less F-actin staining. This 
experiment confirmed simultaneous decrease in F-actin content and PAI-1 
expression upon treatment with inhibitors of actin polymerization.
Stabilization of actin cytoskeleton on TGFp-induced PAI-1 expression
If the hypothesis that the changes in actin cytoskeleton regulate PAI-1 
expression is true and decreased stress fiber content of the cells blocks PAI-1 
expression, then an increase in stress fibers should increase PAI-1 expression. 
Jasplakinolide stabilizes the stress fibers thereby increasing the cellular stress 
fiber content. Jasplakinolide increased basal PAI-1 expression and augmented 
the stimulatory effect of TGF(3 on PAI-1 mRNA and protein expression (Chapter 
5). Treating the cells with agents that increase the stress fiber content tested the 
possibility that enhanced actin cytoskeletal assembly has an effect opposite to 
that of disassembly on PAI-1 expression and essentially rules out the possibility 
that the observed effects of actin depolymerization are artifacts of the use of 
pharmacologic inhibitors The increase in stress fiber content caused by JAS 
could not be visualized since it binds to the F-actin fibers and therefore interferes 
with binding of phalloidin, the agent that helps to visualize F-actin [175]
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To ensure that the increase in PAI-1 expression upon JAS treatment was 
associated with the stabilization of actin cytoskeleton, the cells were pre-treated 
with inhibitors of actin polymerization prior to JAS treatment (Chapter 5). Co­
treatment with actin depolymerizing agents such as CytB, Toxin B and Y-27632 
blocked the stress fiber formation and reversed the effects of Jasplakinolide on 
PAI-1 expression. Thus, the changes in actin polymerization correlate with 
changes of PAI-1 expression. Taken together, these results indicate that Rho 
modulates the ability of TGFp to regulate PAI-1 expression by controlling the 
state of actin polymerization and that the actin cytoskeleton mediated changes in 
TGFp-induced PAI-1 expression depend upon the degree of its organization.
The findings of this study are based on pharmacological agents. The 
effects of pharmacological inhibitors may show non-specific effects. However, 
multiple agents using unique mechanisms of action showed a similar effect 
suggesting that the effects are specific to the treatment effect. Still, the use of 
constitutively active or dominant negative mutants may provide further 
confirmation of the observations.
The opposing effects of actin depolymerization and stabilization on PAI-1 
expression are consistent with similar effects on a1 (I) collagen, a component of 
ECM, by Schnaper et al [87], They showed inhibition of TGFp-mediated 
expression of a1 (I) collagen by actin depolymerization [87], In the same study 
they showed that stabilization of stress fibers with JAS antagonized the inhibitory 
effect of actin depolymerization. These results also show that the degree of 
organization of actin cytoskeleton correlates with net ECM deposition. Since
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collagen and PAI-1 both contribute to ECM accumulation, it is plausible that both 
the genes are regulated by similar or coordinated mechanisms. Studies have 
shown that Rho-kinase inhibition also inhibits PAI-1 expression in response to 
other agonists such as Ang II [81]. This is consistent with the hypothesis that 
changes in actin polymerization may act as a final common pathway that 
modulates the effect of multiple extracellular stimuli on gene expression.
The effect of actin cytoskeleton on PAI-1 promoter activity
Once the role of actin cytoskeleton in regulation of PAI-1 expression was 
confirmed, the subsequent studies aimed to determine the mechanism of this 
regulation. Since PAI-1 expression is mainly regulated at the level of 
transcription, the effects of actin cytoskeleton on PAI-1 transcription were 
examined using human PAI-1 promoter (Chapter 6).
The mechanism of PAI-1 mRNA regulation by cytoskeleton was 
investigated by examining the effects of actin depolymerization on PAI-1 
promoter activity. First, an 1100 bp human PAI-1 promoter containing major 
regulatory elements was cloned into a luciferase vector. The identity of the 
cloned promoter was confirmed by sequencing. Due to difficulties in transfecting 
primary cultured human mesangial cells, initial experiments were performed in rat 
mesangial cells. The rat and human PAI-1 promoter contain similar regulatory 
elements, albeit in different numbers. Dual luciferase assay system containing 
firefly luciferase under the control of PAI-1 promoter and renilla luciferase under 
minimal thymidine kinase promoter was used to transfect rat mesangial cells.
The renilla luciferase was used to normalize for transfection efficiencies. In the
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initial time-course experiment with TGFp, no changes in renilla luciferase were 
obtained upon different treatments. Normalized PAI-1 values show that TGFp 
increases PAI-1 promoter activity marginally in rat mesangial cells. The efforts to 
reproduce similar experiment in human mesangial cells failed to show consistent 
counts for renilla luciferase activity. Consequently, luciferase values from human 
mesangial cells were normalized to the protein concentration of the sample. The 
luciferase values were represented as luciferase count/pg protein. Studies with 
human mesangial cells show ~250% increase in human mesangial cells. This 
effect is consistent with previous studies with the same PAI-1 promoter [112].
This increase is also consistent with the increase in PAI-1 mRNA and protein 
expression seen upon TGFp treatment. Since the fold-increase in PAI-1 promoter 
and mRNA are similar, the regulation of mRNA seems to be at the transcriptional 
level. These findings are consistent with previous reports suggesting PAI-1 
mRNA is mainly regulated at the level of transcription [136, 137], Treatment with 
CytB blocked basal as well as TGFp-induced PAI-1 promoter activity suggesting 
critical requirement of organized actin cytoskeleton for PAI-1 expression.
Although it is not completely known how changes in actin polymerization 
regulate PAI-1 promoter activity, there are several possible mechanisms that can 
explain this regulation. Since PAI-1 promoter is rich in regulatory elements, it is 
possible that actin depolymerization alters the binding of transcriptional factors to 
the regulatory elements in PAI-1 promoter. Alternatively, the binding to yet 
uncharacterized PAI-1 promoter elements may be altered by actin 
depolymerization. As described previously in the thesis, there are potential
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similarities in the regulation of PAI-1 and a-SMA. The promoter region of a-SMA 
contains CArG elements, which are sensitive to changes in actin polymerization 
[176], Hautmann et al have shown cooperation between TGFP-responsive 
elements and CArG elements for TGFp-induced expression of a-SMA [177], 
Although, CArG elements have been shown only in uPA promoter so far, other 
yet unidentified cytoskeleton-responsive elements may drive PAI-1 promoter in 
concert with TGFp-response elements [178], Another possible mechanism may 
involve Nuclear Factor Yin Yang 1 (YY1). In myofibroblasts YY1 represses 
expression of a-SMA and TGFP-responsive genes such as PAI-1 [179]. Ellis et al 
have shown that YY-1 competes with serum response factor (SRF) for binding to 
serum response elements (SRE) in the a-SMA promoter. F-actin inhibits this 
repressive effect of YY1 on a-SMA expression, thereby increasing a-SMA 
expression [180]. Conversely, G-actin inhibits a-SMA expression by facilitating 
repression by YY1. Similarly, YY1 competes with SMAD for binding to the PAI-1 
promoter and blocks TGFp-induction of PAI-1 promoter [179]. Although, it is a 
potential mechanism of regulation of PAI-1 expression by changes in actin 
cytoskeleton, no direct evidence linking actin cytoskeleton and YY1-binding to 
PAI-1 promoter has been shown so far. In future studies, this can be examined 
by performing an electrophoretic gel mobility-shift assay on the nuclear extracts 
from the cells treated with actin depolymerizing or stabilizing agents. Given the 
facilitation of YY1 binding to promoter elements by G-actin, an increase in G- 
actin content upon actin depolymerization is expected to result in the 
displacement of SMAD binding to SMAD-binding sites by YY1, and vice versa by
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increase in F-actin content. Alternatively chromatin immunoprecipitation (ChIP) 
assay can be used to identify interaction of YY1 or other potential regulatory 
factors to PAI-1 promoter elements [181].
The effect of actin cytoskeleton on plasminogen activators
Having confirmed the regulation of PAI-1 expression by the actin 
cytoskeleton, the regulation of other members of plasminogen activators system 
was examined next. The effects of TGFp and actin cytoskeleton on tPA and uPA 
expression were examined in the same set of samples that were used to study 
PAI-1 expression.
An eight hour treatment with TGF(3 caused a small but statistically 
significant inhibition of tPA mRNA expression (Chapter 6). This effect is 
consistent with the role of TGF[5 as a profibrotic growth factor. Previously, 
however, Baricos et al did not see any significant effect of TGF(3 on tPA protein in 
cultured human mesangial cells at 72 hours [89]. The effect of TGF[3 observed on 
tPA mRNA expression in the current study was small and remains to be 
confirmed at the protein level. This small effect could represent the variability 
among different mesangial cell isolates or the effect of differences between the 
treatment periods. At the same time, inhibition of actin polymerization increased 
basal tPA mRNA expression and reversed the inhibition exerted by TGF(3. This 
finding is particularly interesting in that it shows coordinated regulation of the two 
genes by the actin cytoskeleton. Simultaneous inhibition of PAI-1 expression and 
upregulation of tPA allows tPA to act unopposed by PAI-1 resulting in a fibrolytic 
state. These results are in agreement with previous studies showing increased
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tPA expression and fibrolytic activity by simvastatin, an HMG CoA reductase 
inhibitor that inhibits Rho activation in human vascular smooth muscle cells, 
endothelial cells and peritoneal mesothelial cells [173, 182, 183], These studies 
provide indirect evidence that inhibition of Rho activation increases tPA 
expression. The current study provides direct evidence that inhibition of Rho- 
mediated actin polymerization increases tPA expression in human mesangial 
cells and that there is a coordinated regulation of the plasminogen activation 
system by the actin cytoskeleton. If the effect seen at the mRNA levels is 
sustained functionally, it favors increased breakdown of ECM by tPA upon 
treatment with actin depolymerizing agents, a potential utility in breaking down 
ECM from sclerosed glomeruli of diseased kidneys.
The coordinated regulation of PAI-1 and tPA may result from the extensive 
homology between 5’ -flanking regions of PAI-1 and tPA genes [115], Bosma et 
al observed only six gaps during alignment of 521 positions of 5’ sense strand of 
PAI-1 (non-coding) with 5’ antisense strand of tPA (coding). The presence of 
extensive nucleotide homology, although on opposite strands, may allow 
common regulatory factors to drive the expression of PAI-1 and tPA coordinately. 
Accordingly, changes in actin cytoskeleton may change the binding of regulatory 
factor to PAI-1 and tPA coordinately. In fact, a coordinated increase in the 
expression of expression of PAI-1 and tPA has been shown in vivo in association 
with stress, surgery and myocardial infarction; and in vitro by endothelial cells in 
response to thrombine, histamine and glucocorticoids [115].
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On the other hand, uPA expression was increased by TGF(3 (Chapter 7). 
The increase seen in uPA by TGFp is consistent with a similar increase shown 
by Baricos et al. [89]. However, they showed that although TGFp increased both 
uPA and PAI-1 expression, the net effect was inhibition of plasminogen activation 
by PAI-1, suggesting that the increase in PAI-1 overcomes the increase in uPA in 
human mesangial cells. Therefore, the TGFp-mediated increase in uPA mRNA 
may not be functionally significant. In the current study, the net effect of TGFp on 
ECM turn over was not examined. The effects of actin depolymerization on uPA 
mRNA did not show statistical significance possibly because of too much data 
variability.
Human mesangial cells produce smaller amounts of uPA and may not 
respond consistently to TGFp-treatment [155]. Alternatively, increasing the 
sensitivity of the mRNA detection protocol may minimize the data variation. 
Overall, the observation that the actin cytoskeleton regulates tPA and PAI-1 but 
not uPA in mesangial cells is consistent with the conclusions of Baricos et. al. 
that tPA has a more important role in ECM turnover. They reported that loss of 
uPA had no effect on plasminogen activation in mesangial cells from uPA knock 
out mice. In contrast, tPA null mesangial cells showed defective plasminogen 
activation [61],
The tPA and uPA proteins could not be detected from the conditioned 
media using Western blot analysis despite multiple optimization attempts. The 
amounts of tPA and uPA expression are much smaller as compared to PAI-1. 
Using conditioned media from cultured human mesangial cells, Baricos et al
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showed a large molar excess of PAI-1 (1.2 ± 0.1 x 10'9 M) over uPA (1.2 ± 0.1 x 
10'12 M) and tPA (0.19 ± 0.04 x 10'9M) [155]. The expression levels for PAI-1 
mRNA (0.01 pg range) in the current study were also at least 10 fold higher than 
those for tPA and uPA (0.001 pg range). These low levels of tPA and uPA protein 
expression may be below the level of detection for Western blot analysis. In 
future, more sensitive detection methods such as ELISA may be helpful in 
detecting tPA and uPA from conditioned media.
Taken together, the results of tPA and uPA analysis show that TGF(3 
inhibited tPA mRNA and increased uPA mRNA expression. Actin 
depolymerization increased tPA expression under basal and TGF(3-treated 
conditions. As discussed earlier, the PAI-1 expression is inhibited under similar 
culture conditions. The coordinated regulation of tPA and PAI-1 by actin 
cytoskeleton could be useful therapeutically in countering fibrosis.
In summary, this study supports the concept that actin cytoskeleton 
can modulate gene expression by regulating intracellular signal transduction. It 
provides initial evidence that the inhibition of actin polymerization may 
coordinately block the expression of profibrotic genes (such as PAI-1) and 
increase the expression of anti-fibrotic genes (such as tPa and uPA). Agents that 
inhibit actin polymerization can be potentially beneficial in the treatment of 
sclerotic diseases.
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CHAPTER 9 
CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions
In summary, TGFp increased PAI-1 expression in human mesangial cells. 
Depolymerization of actin cytoskeleton using inhibitors of Rho and Rho-kinase 
inhibited PAI-1 expression. The effects of Rho-inhibition were mimicked by direct 
inhibition of actin cytoskeleton suggesting that the effects of Rho-inhibition were 
mediated through actin cytoskeleton. On the contrary, stabilization of actin 
cytoskeleton increased basal and TGFp-mediated PAI-1 expression. Thus bi­
directional changes in the organization of actin cytoskeleton were followed by 
changes in the PAI-1 expression suggesting modulation of gene expression by 
the actin cytoskeleton. Inhibition of actin polymerization also blocked PAI-1 
promoter activity suggesting transcriptional regulation of PAI-1 expression by the 
actin cytoskeleton. In contrast to the inhibition of PAI-1 expression, tPA 
expression was increased by te actin depolymerization by both direct inhibitors 
and inhibitors of Rho-signaling. Thus, changes in actin cytoskeleton mediate the 
effects of Rho-GTPases in modulating PAI-1 and tPA expression in response to 
TGFp. The opposite regulation of PAI-1 and tPA suggests a coordinated gene 
regulation by the actin cytoskeleton whereby they may control ECM degradation. 
The results of the current studies with PAI-1 and tPA combined with the previous 
work on a-SMA and hypertrophy suggest that changes in organization of the
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actin cytoskeleton regulate myofibroblast differentiation and ECM accumulation 
by coordinately modulating expression of multiple genes.
Among the number of interesting questions that arise from these 
observations, two particularly interesting ones were addressed first to explore 
future directions. (1) What intracellular signaling pathways are regulated by 
changes in actin polymerization during the modulation of TGFp-induced PAI-1 
expression? (2) Can agents that inhibit actin polymerization, including inhibitors 
of Rho, protect against fibrosis by inhibiting PAI-1 expression in vivo in animal 
models? The first question was the logical next step in characterizing the 
mechanism of cytoskeleton mediated gene regulation. The second question 
addressed the clinical usefulness of the findings of this study.
Role of MAPK in TGFP-induced PAI-1 expression 
Introduction
Results discussed in chapters 3 through 7 showed that the Rho-mediated 
changes in actin cytoskeleton modulate induction of PAI-1 in response to 
extracellular stimulus such as TGFp. The intracellular signaling pathways 
involved in this regulation are not known. SMAD proteins, being the primary 
intracellular mediators of TGFp, are potential candidates. However Tsuchida et al 
recently showed that SMAD4, essential in SMAD-dependent target genes 
responses, regulates only the early (2 hours) TGFp-mediated PAI-1 response 
and not the sustained PAI-1 response in mesangial cells [184], Thus, it appears 
that non-SMAD intracellular signaling pathways may also regulate TGFp-induced 
PAI-1 expression. This observation is supported by findings that the effects of
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SMAD and mitogen-activated protein kinases (MAPKs), a group of serine- 
threonine kinases consisting of three sub-families of intracellular signal 
transducers, are additive in achieving maximum TGFp-dependent responses in 
human mesangial cells [185]. TGFp-induced PAI-1 expression has been shown 
to require MAPK in a cell-type specific manner [186-190], TGF(3-mediated PAI-1 
expression requires extracellular signal regulated kinase (ERK) in astrocytes and 
renal epithelial cells [188, 189], p38 in hepatocytes and fibroblasts [186, 190], 
and c-jun-NH2 terminal kinase (JNK) in MvlLu epithelial cells [187], The 
requirement of MAPK for TGF-P mediated PAI-1 expression has not been 
examined yet in human mesangial cells.
Recently, Schnaper et al have showed that TGFp-induction of collagen 
gene expression requires ERK activation [191]. Also, actin depolymerization 
blocks TGFp-induced collagen expression [87]. Taken together these studies 
suggest that actin depolymerization blocks TGFp-induced collagen expression by 
inhibiting ERK activation. Similarly, TGFp may be activating MAPK to induce PAI- 
1 in an actin cytoskeleton dependent manner. The hypothesis that the actin 
cytoskeleton modulates TGFp-induced PAI-1 expression by modulating MAPK 
activation was proposed. As a first step towards examining this hypothesis, the 
requirement of MAPKs in TGFp-induced PAI-1 expression was examined in 
human mesangial cells.
Working hypothesis
TGFp-induced PAI-1 expression in human mesangial cells requires 
activation of MAPK pathway in a cytoskeleton dependent manner.
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Experimental model
To examine the requirement of MAPK in TGFP-mediated PAI-1 
expression, pharmacological inhibitors of MAPK were used block MAPK 
signaling. The efficacies of reported effective concentrations of MAPK inhibitors 
were confirmed in human mesangial cells in the lab prior to the use. The 
literature indicated that the effective doses were 30 pM for PD98059, the ERK 
inhibitor [192], 5 pM for SB203580, the p38 inhibitor [193] and 10 pM for 
SP600125, the JNK inhibitor [194], These kinase inhibitors were relatively 
specific at the doses used in the study. PD98059 and SB203580 were found 
specific inhibitors of ERK and p38 respectively with minimal inhibition of other 
kinases at doses higher than those used in this study [195], SP600125 was 
found >20-fold selective inhibitor of JNK at IC5o of 10 pM, the same dose as used 
in this study [196].
To examine if one or more of the three MAPKs were required for TGFp- 
induced PAI-1 activation in human mesangial cells, serum-starved mesangial 
cells were pre-treated with MAPK inhibitors followed by TGFp-treatment. The 
effects on PAI-1 mRNA and protein expression were examined.
Results
Since TGFP activates different MAPK modules depending on the cell type 
and the target gene, the requirement of each of the three MAPK for TGFp 
mediated PAI-1 expression in human mesangial cells was examined first. Serum- 
starved human mesangial cells were pre-treated for one-hour with 30 pM 
PD98029, 5 pM SB203580 and 10 pM SP600125 to inhibit ERK, p38 and JNK
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respectively. Cells were then treated with 10 ng/ml TGFp for 8 hours (mRNA 
analysis) or 24 hours (protein analysis). Real-time PCR analysis showed that 
inhibition of ERK, p38 and JNK changed PAI-1 mRNA expression in serum-free 
media to 94.6 ± 10.8%, 87.2 ± 6.6% and 82.7 ± 14.0% of untreated control 
respectively. None of the effects were statistically significant. However, ERK and 
JNK inhibition blocked TGFp-induced PAI-1 expression to 64.7 ± 14.7% (p=0.06) 
and 52.7 ± 4.7% (p<0.005) of TGFp-treated control respectively. Inhibition of p38 
increased PAI-1 expression to 114.9 ± 5.7% of TGFp-treated control (p=0.05) 
(Fig. 32).
Western blot analysis of conditioned media (n=3) showed that ERK and 
JNK inhibition inhibited basal PAI-1 expression to 70.6 ± 13.2% and 64.3 ± 
14.5%of untreated control respectively (p<0.05). Inhibition of p38 had no 
significant effect on basal or TGFp-induced The PAI-1 protein expression (96.6 ± 
12.4%). However, ERK and JNK inhibition blocked TGFp-induced PAI-1 
expression to 49.5 ± 12.6% (p<0.005) and 44.4 ± 12.6% (p<0.001) of TGFp- 
treated control respectively. Inhibition of p38 changed PAI-1 expression to 
90.7 ± 5.0% of TGFp-treated control (Fig. 33).
From these results both ERK and JNK appear to be required for TGFp- 
induced PAI-1 expression whereas p38 is not required for basal or TGFp-induced 
PAI-1 expression.
Discussion
The main focus of this study was to identify which, if any, of the MAPK 
was being activated by TGFp for PAI-1 regulation. Inhibitors of ERK and JNK
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Fig. 32. Effect of MAPK inhibition on PAI-1 mRNA expression. Serum- 
starved human mesangial cells were pre-treated for one-hour with 30 pM 
PD98029, 5 pM SB203580 and 10 pM SP600125 to inhibit ERK, p38 and JNK 
respectively. Cells were then treated with 10 ng/ml TGFp for 8 hours followed by 
quantitative real-time PCR analysis of mRNA. The vertical bars and the error 
bars represent the mean value for PAI-1 mRNA and SEM respectively. The value 
for untreated control is set at 100%. *: p<0.005 compared to S-, f :  p=0.06 
compared to TGFp, t t :  p=0.05 compared to TGFp, t t t :  P<0.05 compared to 
TGFp (n=3).
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Fig. 33. Effect of MAPK inhibition on PAI-1 protein expression. Serum- 
starved human mesangial cells were pre-treated for one-hour with 30 pM 
PD98029, 5 pM SB203580 and 10 pM SP600125 to inhibit ERK, p38 and JNK 
respectively. Cells were then treated with 10 ng/ml TGFp for 24 hours followed 
by Western blot analysis of conditioned media (n=3). Repersentative blot is 
shown in panel A. Panel B shows graphical representation of three separate 
experiments. The vertical bars and the error bars represent the mean value for 
PAI-1 protein and SEM respectively. The value for untreated control is set at 
100%. *: p<0.05 compared to S-, **: p<0.005 compared to S-, f .  p<0.01 
compared to TGF(3, t f :  p<0.005 compared to TGFp.
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blocked TGFp-induced PAI-1 mRNA and protein expression suggesting their 
involvement in TGFP signaling. The requirement of ERK is consistent with 
studies showing involvement of ERK in Angiotensin, vascular endothelial growth 
factor and platelet derived growth factor induced PAI-1 expression [81, 197, 198], 
Involvement of JNK is consistent with regulation of thrombin-induced PAI-1 
expression by JNK [199], Overall, the findings are also similar to the results of 
Schnaper et al showing activation of ERK and JNK but not p38 by TGFp in 
human mesangial cells [191]. The requirements for ERK and JNK may result 
from their roles in regulating AP-1 dependent transcription of PAI-1. In fact, a 
study published during the preparation of this thesis showed a requirement of 
MAPK/AP-1 activation for TGFp-induced PAI-1 expression in rat mesangial cells 
[200]. This published result confirmed the original hypothesis proposed in this 
lab.
The treatment with ERK and JNK inhibitors in serum-free media blocked 
basal PAI-1 protein expression but did not change PAI-1 mRNA expression. This 
finding suggests that under basal condition, post-transcriptional regulation of PAI- 
1 may contribute to the reduction in protein levels by ERK and JNK inhibitors. 
Conversely, inhibition of p38 resulted in a small but significant increase in TGFP- 
induced PAI-1 mRNA expression. The increase may result from increased 
activity of ERK and JNK upon p38 inhibition as shown by Ohashi et al [201].
In summary, the results confirm a requirement for ERK and JNK in TGFp- 
induced PAI-1 expression in human mesangial cells. However, the specificity of 
the effects of pharmacological inhibitors has to be ultimately confirmed using
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dominant negative mutants of each of the three MAPKs. Although the study is 
focused mainly on identifying the role of MAPK as the intracellular mediator of 
TGFp signaling, it is appreciated that TGFp signaling may involve other 
intracellular signaling molecules such as protein kinase A (PKA) and protein 
kinase C (PKC) for the regulation of PAI-1 expression. The activation of ERK and 
JNK upon TGFp-treatment can be examined to show a direct evidence for the 
role of MAPK in TGFp signaling. The role of actin cytoskeleton in modulation of 
ERK and JNK activation can be studied by examining the changes in ERK and 
JNK activation upon inhibiting or stabilizing the actin cytoskeleton. The 
confirmation of the role of actin cytoskeleton in modulating MAPK activation in 
TGFp-induced PAI-1 expression will explain the mechanism of action of 
cytoskeleton modifying agents. Overall, the elucidation of specific mechanism of 
gene regulation by the actin cytoskeleton will provide avenue for future research 
into identifying more specific targets of actin cytoskeleton in the regulation of 
intracellular signaling and gene expression.
Effect of Rho-kinase inhibition on sclerosis in chronic mesangiosclerotic 
glomerulonephritis
Introduction
The results of cell culture experiments showed coordinated regulation of 
two members of plasminogen activator system, PAI-1 and tPA, by the Rho- 
mediated changes in actin cytoskeleton (Chapters 3 through 7). The functional 
significance of these changes in plasminogen activator system was determined 
next by examining the effect on ECM degradation in vivo.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
140
Regulation of ECM turnover is one of the major functions of the 
plasminogen activator system [56]. Increased intraglomerular deposition of ECM 
proteins resulting in glomerulosclerosis is a major feature of chronic renal 
diseases. [202], Increased ECM deposition may result from inhibition of ECM 
breakdown by TGFp-induced PAI-1 expression in chronic glomerulosclerotic 
renal diseases [59]. The in vitro results of this study show that inhibition of Rho- 
mediated actin polymerization inhibits TGFp-induced PAI-1 expression. In vivo 
inhibition of ROCK by Y-27632 is also shown to protect against tubulointerstitial 
fibrosis in a unilateral ureteral obstruction model [104], These observations 
suggested the possibility that if Rho-kinase inhibitors had similar inhibitory effect 
on PAI-1 expression in vivo, it could protect against ECM deposition and 
glomerulosclerosis.
Working Hypothesis
Rho-kinase activation increases expression of PAI-1 compared to tPA and 
uPA, and thus causes mesangial matrix expansion. Treatment of rats with Rho- 
kinase inhibitor, HA-1077, will block these changes and provide a protective 
effect against glomerulosclerosis
Experimental model
A single injection of anti-Thy 1.1 antibody, that reacts with a Thy 1-like 
antigen on the surface of glomerular mesangial cells, leads to a disease 
characterized by mesangial proliferation and, deposition of collagen and fibrin in 
mesangium [203]. However, this injury is self-limited and resolves as early as 6
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weeks [204], Repeated injections of anti-Thy 1.1 antibody have been reported to 
produce a more severe form of glomerulonephritis with unresolved 
glomerulosclerosis akin to the lesions seen in chronic glomerulonephritis [202, 
205], This model system was used to examine effectiveness of ROCK-inhibitor 
in prevention and treatment of ECM accumulation in chronic renal diseases.
In order to cause mesangiaosclerotic glomerulonephritis rats were given 
four weekly injections of Thy 1.1 antiserum (ATS) containing anti-Thy 1.1 
antibody as described in the chapter 2. Each ATS injection was followed by 
injection of goat serum to provide complement for fixation of the antibody. Also, 
after four weekly injections, the animals were observed/treated for six more 
weeks to produce progressive injury [206]. The Rho-kinase inhibitor HA-1077 
was used in this study to treat the animals because of its specificity at the dose 
used in the study, water-solubility for ease of administration and lower expense. 
Moreover, it is already under clinical trials for the use in human patients suffering 
from stroke suggesting its potential use in humans [207, 208], The 
glomerulosclerotic injury was visualized by histology and immunohistochemistry. 
Twenty-four hour urinary protein excretion and serum creatinine levels were 
measured as indicators of glomerular injury.
Results
Histopathologic grading of glomerular ECM deposition and injury
The histological sections were stained by Masson trichrome method. The 
slides were coded before the analysis. Sclerosis was graded on a scale of 0 for 
normal to 3+ for diffusely increased trichrome-positive (blue) mesangial matrix
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material. Scores of 2+ and 3+ correspond to focally positive or intermediate 
staining intensity of trichrome-positive glomeruli. A practicing renal pathologist 
performed grading of trichrome-stained sections. The code was broken only after 
completion of the grading. The average score of control rats was 0.8 ± 0.3 (s.e.) 
while the group with ATS administration had average score of 1.7 ± 0.6. Rats 
treated with HA-1077 had an average score of 1.0 both whether the therapy was 
initiated before (s.e. 0.5) or after (s.e. 0.3) the first ATS injection (Table 5). While 
these results suggest that the therapy with HA-1077 may have been beneficial, 
none of these differences achieved statistical significance at a confidence level of 
p < 0.05.
The sections were also stained for smooth muscle a-actin (a-SMA) to 
examine myofibroblast differentiation in mesangial cells. For each animal, 100 
glomeruli were sequentially analyzed at 40X objective. The glomeruli showing 
clear non-hilar staining for a-SMA were counted as positive. The results were 
similar to those seen with trichrome staining. The percentage of positive 
glomeruli were: 0.8% ± 0.5% in normal control rats, 3.8% ± 2% in ATS-treated 
rats and, 2.5% ± 0.6% in rats treated with HA-1077 before and after the ATS 
injection (Table 5). Again, none of these results showed any statistically 
significant difference between treated and untreated groups.
Effect on urinary protein excretion
Urinary protein results at the end of the study were consistent with production of 
mild glomerular injury (Table 5). The control rats excreted 14.6 ± 1.7 mg protein/ 
24 h, ATS-treated rats excreted 35.0 ± 11.0 mg protein/ 24 h (p<0.05).
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Fig. 34. Effect of Rho-kinase inhibition on sclerosis in a rat model of 
chronic glomerulonephritis. Animals were divided into four groups as follows: 
Group 1: Normal saline injection alone (A), Group 2: ATS-complement injection
(B), Group 3: ATS-complement+ HA-1077 treatment started 1 day before the first 
injection (C), Group 4: ATS-complement+HA-1077 treatment started 1 week after 
the first injection (D). Trichrome staining of representative glomeruli show 
increased mesangial sclerosis in group 2 (B) and, a relative decrease in groups 3
(C) and 4 (D) suggesting a protective effect of Rho-kinase inhibition. The 
arrowheads mark mesangial ECM deposition stained blue by trichrome staining.
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Table 5. Effect of Rho-kinase inhibitor on experimental glomerulonephritis
Group 24-hour urinary 
protein 
(mg)
Serum
creatinine
(mg/dL)
Histological
grading
(0-3)
a-SMA 
staining 
(% positive)
1.Control 14.6 ± 1.7 1.18 ± 0.16 0.8 ±0.3 0.8 ±0.5
2. Disease, 
no treatment
35.0 ±11.0 (p< 0.05) 1.41 ±0.2 1.7 ±0.6 3.8 ±2.0
3. Disease, 
Pre-treatment
19.0 ±2.1 (p=0.09) 1.07 ±0.14 1.0 ±0.5 2.5 ±0.6
4. Disease, 
post-treatment
24.42 ± 3.9 (p=0.12) 1.21 ±0.18 1.0 ±0.3 2.5 ±0.6
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Rats started on therapy with HA-1077 before the first ATS injection excreted 19.0 
±2.1 mg protein/24 h (p=0.092 as compared to untreated group), whereas rats 
started on therapy one week after the first injection had 24.42 ± 3.9 mg 
protein/24 h (p=0.193 as compared to untreated group). SDS-PAGE analysis of 
urinary proteins showed that albumin was the major urinary protein.
Effect on serum creatinine levels
Serum creatinine measurement at the end of the study followed the same 
trends as urinary proteins, but again failed to reach statistical significance for the 
treatment effect. These values were: control 1.18 ± 0.16 mg/dl, ATS only 1.41 ±
0.2 mg/dl, HA-1077 started before ATS; 1.07 ± 0.14 mg/dl; and, HA-1077 started 
after ATS; 1.21 ± 0.18 mg/dl (Table 5).
Determination of drug efficacy
HA-1077 solutions used in the study effectively inhibited actin 
polymerization in cultured human mesangial cells throughout the treatment 
period suggesting that the drug was stable in water.
There were no significant differences between groups in kidney to body 
weight ratio, blood pressure, daily water consumption and daily urine output.
Discussion
The results of the histologic scoring, a-SMA staining, urinary protein and 
serum creatinine values all suggest the same conclusion, that the Rho-kinase 
inhibitor, HA-1077 had a beneficial effect on glomerular injury in this chronic 
model of mesangial sclerotic glomerulonephritis (Table 5). Although none of 
these results individually achieved statistical significance, these studies provide
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initial evidence that a Rho-kinase inhibitor could be useful in the treatment of 
glomerulosclerosis. In future optimization of the disease model may yield 
statistically significant results. At this stage, this chronic model is difficult to 
reproduce (personal communication between Dr. Glass, the principle 
investigator, and other investigators in the field).
Several factors may contribute to the inability of the results to achieve 
statistically significant differences between the study groups. First, the degree of 
mesangial sclerosis was mild even in the most severely affected rats. Thus a 
model with more severe mesangial injury will be necessary. Border et al. allowed 
18 weeks (instead of 10 weeks as used in this study) for the progression of the 
disease in their study [206]. Alternatively, more experimental models with more 
invasive procedures such as surgical renal ablation could be used to produce 
severe injury [209, 210]. Second, a larger study with more animals in each group 
may help the trends seen in the result achieve a statistical significance. Third, the 
effect of treatment was inconsistent, making it difficult to grade the injury even by 
an experienced pathologist. Although the drugs used in these studies were active 
and effective in blocking stress fiber formation in cell culture, their in vivo 
effective dose could not be assessed. Optimization of therapeutic dose in this 
particular model system could potentially give more consistent therapeutic 
effects.
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From: "Patel, Keyur MD" <KPatel1@LIJ.EDU>
To: '"pripka@ the-aps.org<pripka@the-aps.org>
Date: 11 /30/2005 5:57:14 AM
Subject: Request for permission to use a figure for thesis preparation
Dear Sir/Madam,
I am a graduate student at Eastern Virgnia Medical School, (Norfolk,
Virginia, USA)currently preparing my written thesis on " Modulation of 
TGF-beta induced PAI-1 expression by changes in actin polymerization in 
human mesangial ceils". I have to present a schematic diagram of PAI-1 
promoter elements. I found "Figure 3: The PAI-1 promoter and consensus 
sequences" from the following articel by Binder et al. very useful.
"Binder, B.R., et al., Plasminogen activator inhibitor 1: physiological and 
pathophysiological roles. News Physiol Sci, 2002. 17: p. 56-61." PUBMED id: 
11909993.
I have created a modified diagram based on the figure 3 of the article 
to show information pertinent to my thesis. I am hereby requesting a kind 
permission to use the modified (not the original) diagram for the thesis.
Please find attached the original and modified diagram for your review.
Also, I am acknowldeding at several places in my thesis that the diagram was 
modified from an original publication by Binder et al and giving a reference 
for the same.
Following is the figure legend I am planning to use with the modified figure 
pending your approval.
"Figure 21: Schematic representation of PAI-1 promoter.-RE, response 
element; TGF&#946;, transforming growth factor: VLDL, very low density 
lipoprotein; CTF, CCAAt box binding transcription factor; NF1, nuclear 
factor 1; PMA, phorbol 12-myristate 13-acetate; AP, activator protein; TRE, 
tetradecanoyl phorbol acetate response element; GRE, glucocorticoid response 
element. Adopted with modification from Binder et al [Binder, 2002 ]."
I will really appreciate your prompt and favorable consideration of my 
request. Your approval will help me immensely in completing my thesis in 
time for submission in December.
Sincerely,
Keyur Patel, MD 
(Ph.D. Candidate)
THE AMERICAN PHYSIOLOGICAL SOCIETY 
9650 Rockvllk Plkt- BHhesda, \1D 20814-3991
Permission is granted for use of the material specified 
above provided tbe publication is credited as the 
source, including the words ’‘used with permission.’’
Haj l a j w g g M '
o
PHbliralioiis Manager &  Executive Editor
The information contained in this electronic e-mail transmission 
and any attachments are intended only for the use of the individual 
or entity to whom or to which it is addressed, and may contain 
information that is privileged, confidential and exempt from 
disclosure under applicable law. If the reader of this communication 
is not the intended recipient, or the employee or agent responsible 
for delivering this communication to the intended recipient, you 
are hereby notified that any dissemination, distribution, copying 
or disclosure of this communication and any attachment is strictly 
prohibited. If you have received this transmission in error, please 
notify the sender immediately by telephone and electronic mail, 
and delete the original communication and any attachment from any
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computer, server or other electronic recording or storage device 
or medium. Receipt by anyone other than the intended recipient is 
not a waiver of any attorney-client, physician-patient or other 
privilege. Thank you.
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